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Abstract 
Cancer is the leading cause of death in economically developed countries and 
the second leading cause of death in developing countries. Lung cancer was the most 
commonly diagnosed cancer as well as the leading cause of cancer death in males in 
2008 globally, accounting for 13% (1.6 million) of the total cases and 18% (1.4 million) 
of the deaths in 2008. Non-small cell lung cancer (NSCLC) is the most common form 
of lung cancer, being is divided into three major histological subtypes, adenocarcinoma, 
squamous cell carcinoma and large cell carcinoma. 
Accumulating evidence shows that miRNAs are grossly deregulated in NSCLC. 
Recent studies have shown that not only can miRNAs be used to sub-classify NSCLCs 
but specific miRNA profiles may also predict prognosis and disease recurrence in early-
stage NSCLCs. 
miRNAs are single‑stranded RNAs (ssRNAs) of approximately 22 nucleotides 
in length that are generated from endogenous hairpin‑shaped transcripts. They have 
become known as key post-transcriptional regulators of gene expression and have 
revolutionized the comprehension of the post-transcriptional regulation of gene 
expression. miRNAs have a big impact on shaping transcriptomes and proteomes as 
they participate in the regulation of every cellular process investigated and changes in 
their expression are associated with many human pathologies, such as cancer. The over-
expression of hsa-miR-196a, in particular, has been associated with different types of 
tumour, however there are some reports indicating that it can also act as a tumour 
suppressor. The role of this miRNA in tumorigenesis is not clear, and data in literature 
indicates that the effects may be cell-type specific. 
Previously to the beginning of this thesis project hsa-miR-196a showed to be 
over-expressed in 29 samples of lung tumours, and this over-expression was also 
confirmed in cell lines derived from different lung cancer histotypes. NCI-H460 
interfered for AKT1 and its infection control SCR also demonstrated a differential 
expression of this miRNA and highest levels of expression were found in NCI-H460 
SCR. In this project, there were created four cell lines in order to evaluate the biological 
effect of hsa-miR-196a and to correlate it to the PI3K/AKT pathway. 
There were chosen 3 predicted targets for hsa-miR-196a whose expression has 
proven to be inhibited by the PI3K/AKT pathway: FoxO1, FoxO3 and p27. Only Foxo1 
and p27 show a reduced luciferase activity indicating the binding of the miRNA to the 
3’UTR. mRNA expression levels all genes did not seem to be affected by the over-
expression or knock-down of hsa-miR-196a1 but the protein levels of FoxO1 and p27 
were reduced in cells expressing the hsa-miR-196a1 vector and increased in cells 
expressing the anti-miR-196a vector, indicating a inhibition of protein synthesis of these 
genes by the miRNA in study. 
Using this cellular system is possible not only to see the effects of the miRNA in 
study but also to correlate the results obtained to the PI3K/AKT pathway.  
The results obtained point to regulation of proliferation and migration by this 
miRNA as its over-expression promotes these processes and the knock-down of its 
expression has a negative effect on them. At least in part the observed effects are due to 
the differential regulation of genes inhibited by the activation of PI3K/AKT pathway. 
 
Keywords: miRNA, miR-196a, PI3K/AKT, Proliferation, Migration, Tumour 
induction in vivo. 
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Resumo 
O Cancro é a maior causa de morte em países desenvolvidos e a segunda em 
países em desenvolvimento. O cancro do pulmão, em específico, foi a forma de cancro 
mais comum diagnosticada assim como a maior causa de morte por cancro em pessoas 
do sexo masculino em 2008, contando com 13% (1,6 milhões) de casos totais e 18% 
(1,4 milhões) de mortes. O cancro do pulmão de não-pequenas células é a forma mais 
comum de cancro do pulmão, sendo dividido em três subtipos histológicos, 
adenocarcinoma, carcinoma de células escamosas e carcinoma de grandes células. 
Um acúmulo de evidências revela que os miRNAs estão bastante desregulados 
em cancro do pulmão de não-pequenas células. Estudos recentes, mostram que os 
miRNAs podem ser utilizados para descriminar entre os diversos histótipos de cancro e 
que a caracterização de miRNAs expressos pode ser útil na previsão de prognósticos e 
recorrência em fases iniciais de cancro do pulmão de não-pequenas células. 
Os miRNAs são RNAs de cadeia simples com aproximadamente 22 nucleótidos 
que são gerados de transcritos com forma de hairpin. São considerados reguladores pós-
transcripcionais da expressão génica e têm revolucionado a compreensão da regulação 
pós-transcripcional, tendo um grande impacto em modulação de transcriptomas e 
proteomas, uma vez que influenciam vários processos celulares já investigados. 
Mudanças nos seus padrões de expressão estão associadas a patologias humanas, como 
o cancro. 
A sobre-expressão do hsa-miR-19611, em particular, foi associada com 
diferentes tipos de cancro, contudo existem artigos que indicam que este miRNA pode 
actuar como um onco-supressor. O papel deste miRNA na tumorigénese não é claro e os 
dados presentes na literatura parecem ser específicos para cada linha celular. 
Antes do início deste projecto, verificou-se a sobre-expressão do hsa-miR-196a1 
em 29 amostras de tumores de pulmão e em linhas celulares de diversos histótipos de 
cancro do pulmão. NCI-H460 interferidas para AKT1 e o seu controlo, SCR, também 
demonstraram uma expressão diferencial deste miRNA e os níveis mais altos eram 
expressos em NCI-H460 SCR. Neste projecto foram criadas quatro linhas celulares de 
modo a avaliar o efeito biológico do hsa-miR-196a e relacioná-lo com a via PI3K/AKT. 
Foram escolhidos 3 alvos previstos para o hsa-miR-196a1 cuja expressão é 
negativamente regulada pela via PI3K/AKT: FoxO1, FoxO3 and p27. Apenas FoxO1 e 
p27 mostraram uma reduzida actividade da luciferase, evidenciando a ligação do miR-
196a aos seus 3’UTR. Os níveis de expressão de todos os mRNAs não se mostraram 
alterados, mas os níveis proteicos de FoxO1 e p27 mostraram-se reduzidos em células 
que expressam o vector contendo o hsa-miR-196a e  aumentados em células que 
expressam o vector contendo o anti-miR-196a, indicando uma modulação da síntese 
proteica destes genes pelo miRNA em estudo.  
Utilizando este sistema celular é possível observar os efeitos deste miRNA e 
também relacionar aos resultados obtidos à via PI3K /AKT. Os resultados obtidos 
apontam para uma regulação da proliferação e migração por este miRNA e a sua sobre – 
expressão promove estes processos e o seu knockdown tem um efeito negativo nos 
mesmos. Pelo menos parte dos efeitos observados são devidos à regulação diferencial 
dos genes inibidos pela activação da via PI3K/AKT, 
  
Palavras-chave: miRNA, miR-196a, PI3K/AKT, Proliferação, Migração, 
Indução de tumores in vivo. 
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I.1. microRNAs 
The first small RNA, lin‑4, was discovered in 1993 by Lee, et al. by genetic 
screens on C. elegans. 
Small RNAs are involved in almost every biological process, including 
developmental timing, cell differentiation, proliferation and death, metabolic control, 
transposon silencing and antiviral defense. 
The eukaryotic small RNAs are distinguished by their limited size (about 20 to 
30 nucleotides) and have been subdivided in three classes: Piwi-interacting RNAs 
(piRNAs), endogenous small interfering RNAs (endo-siRNAs or esiRNAs) and 
microRNAs (miRNAs). The differences among them are based on their biogenesis 
mechanism and the subfamily of Argonaute (AGO) protein, Piwi or AGO, that they are 
associated with. However, there were found numerous non‑canonical small RNAs 
which have blurred the boundaries between the classes. 
piRNAs are 24 to 30 nucleotides (nt) in length, associate with Piwi-subfamily 
proteins and their biogenesis does not depend on Dicer. These molecules are abundant 
in germ cells and at least some of them are involved in transposon silencing through 
heterochromatin formation or RNA destabilization. On the other hand, esiRNAs which 
associate with AGO-subfamily proteins (similarly to miRNAs) are derived from long 
double - stranded RNAs (dsRNAs) and are dependent only on Dicer. They are also 
slightly shorter (~21 nt) than miRNAs. Some of the esiRNAs have been shown to 
function as post‑transcriptional regulators targeting RNAs. 
miRNAs are classified as single‑stranded RNAs (ssRNAs) of approximately 22 
nucleotides in length that are generated from endogenous hairpin‑shaped transcripts, 
being the most understood small RNAs (Kim, et al., 2009). They have become known 
as key post-transcriptional regulators of gene expression in metazoans and plants, and 
have revolutionized the comprehension of the post-transcriptional regulation of gene 
expression. It is becoming clear that miRNAs have a big impact on shaping 
transcriptomes and proteomes of eukaryotic organisms (Siomi and Siomi, 2010). In 
mammals, miRNAs are predicted to control the activity of approximately 60% of all 
protein-coding genes. Functional studies indicate that miRNAs participate in the 
regulation of almost every cellular process investigated so far, like modulation of gene 
expression, chromosome structure, innate immune defence, and that changes in their 
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expression are associated with many human pathologies, such as cancer (Cheloufi, et 
al., 2010; Krol, et al., 2010; Siomi and Siomi, 2010). 
Generally, miRNAs inhibit protein synthesis either by repressing translation 
and/or by bringing about deadenylation and subsequent degradation of mRNA targets. 
More recently, however, some miRNAs were reported to activate mRNA translation. 
miRNAs function in the form of ribonucleoprotein complexes, miRISCs (miRNA-
induced silencing complexes). Argonaute (AGO) and GW182 [glycine-tryptophan 
(GW) repeat-containing protein of 182 kDa] family proteins represent the best-
characterized protein components. Components of miRISC (including miRNAs as well 
as AGO and GW182 proteins) and repressed mRNAs are enriched in processing bodies 
(P-bodies, also known as GW bodies), which are cytoplasmic structures thought to be 
involved in the storage or degradation of translationally repressed mRNAs. 
miRNAs almost always interact with their mRNA targets via imperfect base-
pairing of their 5’ nucleotides 2–8, representing the seed region, with the 3’UTR 
(untraslated region) of target mRNA. Animal miRNAs may also target 5’ UTR and 
coding regions of mRNAs and interestingly association of miRNAs with 5’ UTR target 
sites appears to activate rather than repress translation. In addition, an A residue across 
position 1 of the miRNA and A or U across position 9 improve miRNA activity, 
although they do not need to base-pair with mRNA nucleotides. However, functional 
miRNA sites containing mismatches or even bulged nucleotides in the seed have also 
been identified. 
Complementarity of the miRNA 3’ half is quite relaxed, though it stabilizes the 
interaction, particularly when the seed matching is suboptimal. Generally, miRNA-
mRNA duplexes contain mismatches and bulges in the central region (miRNA positions 
10–12) that prevent endonucleolytic cleavage of mRNA by an RNAi mechanism. AU-
rich sequence context and structural accessibility of the sites may improve their 
efficacy. Usually, multiple sites, either for the same or different miRNAs, are required 
for effective repression, and when the sites are close to each other, they tend to act 
cooperatively (Fabian, et al., 2010). 
miRNAs direct RISC to repress translation of target mRNAs in diverse ways and 
stages. They can block translation initiation or elongation by promoting premature 
dissociation of ribosomes (Figure 1A) or act in cotranslational protein degradation 
(Figure 1B, however the putative protease is unknown. Argonaute proteins compete 
with eIF4E (eukaryotic translation initiation factor 4E), which is essential for cap-
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dependent translation initiation, for binding to the cap structure (Figure 1C); recruit 
eIF6, preventing the large ribosomal subunit from joining the small subunit (Figure 1D); 
and prevent the formation of the closed loop mRNA configuration by an ill-defined 
mechanism that includes deadenylation (Figure 1E). miRNA can also mediate mRNA 
decay by triggering deadenylation and subsequent decapping of the mRNA target 
(Figure 1F) (Eulalio, et al., 2008; Filipowicz, et al., 2008).  
 
Figure 1 – Processes through which miRNAs can repress the translation of a mRNA. Source: Eulalio, 
et al., 2008). 
 
All four human AGO proteins, AGO1–4, bind similarly to identical populations 
of small RNAs, suggesting that human AGO1–4 might not have significantly 
differentiated functions. On the other hand, the catalytic domain remains conserved and 
active only in AGO2 which is especially active in the embrionary phase (Cheloufi et al., 
2010).  
Some miRNAs have tissue-specific expression, modulating lineage-specific 
gene expression and cell cycle progression (Carleton, et al., 2007). 
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Nevertheless, they are themselves subject to sophisticated, tight and dynamic 
regulation at both the levels of miRNA metabolism and function, particularly during 
rapid developmental transition or changes in cellular environment. The numbers of 
individual miRNAs expressed in different organisms (~800 in humans) are comparable 
to those of transcription factors or RNA-binding proteins (RBPs), and many of them are 
expressed in a tissue or developmental stage-specific manner, thus contributing to cell-
type-specific profiles of protein expression. Having the potential to target dozens or 
even hundreds of different mRNAs, individual miRNAs can coordinate or fine-tune the 
expression of proteins in a cell (Kim, et al,. 2009). 
 
 
I. 1.1 microRNAs biogenesis 
I. 1.1.1 microRNA transcription 
miRNAs are manly located in intergenic regions, forming clusters, predicting a 
long transcript encompassing several coordinated expressed miRNAs. Generally 
miRNAs can be classified in three groups according to their genomic localization: 
exonic miRNAs in non-coding transcription units, intronic miRNAs in non-coding 
transcription units or intronic miRNAs in protein coding transcription units (Gregory 
and Shiekhattar, 2005; Kim, 2005). 
In the canonical biogenesis process, microRNAs are processed from precursor 
molecules that are called Primary miRNA (pri-miRNAs) (Chong, et al., 2010; Krol, et 
al., 2010). pri-miRNAs are several kb long molecules with a stem of 33 bp, a terminal 
loop and flanking ssRNA segments. These molecules are transcribed by RNA 
polymerase II (Pol II) from specific transcripts of independent genes and they often 
produce more than one functional miRNA (Krol, et al., 2010; Siomi and Siomi, 2010). 
Transcription by Pol II allows the differential expression control of miRNAs and leaves 
specific structures such as 5’ cap structures and poly-A tails (Kim, 2005; Miyoshi, et 
al., 2010). Promoters of some miRNAs although able to direct Pol II-dependent 
transcription, lack all typical promote elements normally required for transcription 
initiation (Gregory and Shiekhattar, 2005). 
There are some non-canonical processes by which specific miRNAs can be 
processed. Mirtrons, which are pre-miRNA-like hairpins that are made by splicing and 
debranching of short hairpin introns are also transcribed by RNA polymerase II from 
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short introns in protein-coding genes. On the other hand, the minor group of 
microRNAs which is associated with Alu repeats and the miRNAs encoded by the 
major cluster in humans are transcribed by RNA polymerase III (Kim, et al., 2009; 
Winter, et al., 2009; Chong, et al., 2010; Siomi and Siomi, 2010). Both polymerases are 
regulated differently and recognize specific promoter and terminator elements, 
facilitating a wide variety of regulatory options (Winter, et al., 2009). 
I. 1.1.2 Pri-miRNAs cleavage by Microprocessor complex 
pri-miRNAs are substrate for a member of the RNA polymerase III enzyme 
family, Drosha, that acts in the nucleus. 
In humans, Drosha associates with its cofactor through the amine domains, the 
DiGeorge syndrome critical region gene 8 (DGCR8) protein to form the Microprocessor 
complex (Kim, et al., 2009). Drosha has two RNase III domains and one dsRNA 
binding domain (Kim, 2005). DGCR8 interacts with pri‑miRNAs through the ssRNA 
segments and the stem of ~33 bp and orients the catalytic core of Drosha to cleave it 
asymmetrically ~11 bp away from the ssRNA–dsRNA junction, leaving a stem loop 
structure – the precursor-miRNAs (pre-miRNAs). Pre-miRNAs, are molecules with 
approximately 70 nt, a 22 nt hairpin stem, a 3’ overhang of approximately 2 nt and a 
terminal loop (Gregory and Shiekhattar, 2005; Winter, et al., 2009; Siomi and Siomi, 
2010). 
Recent studies show that intronic miRNA processing by Drosha might take place 
after the transcript is tied to the early spliceosome complex, but before the intron is 
excised and the first process does not influence the second. Cropping and splicing of 
pri-miRNAs might be highly coordinated co‑transcriptional processes.  The nuclear 
exosome (which comprises 3′→5′ exonucleases) and XRN2 (a 5′→3′ exonuclease) also 
associate with the intronic miRNA hairpin region and promote the degradation of the 
fragments (Kim, et al., 2009; Winter, et al., 2009). Drosha can also cleave other 
mRNAs that contain long hairpins from protein -coding genes, non-coding genes or 
structural RNAs, although it is not as efficient as for miRNAs. One example is the 
second exon of the DGCR8 mRNA, meaning it regulates its own cofactor, negatively 
(Kim, et al., 2009; Chong, et al., 2010). When the miRNA hairpin is located in the 
exonic region, Drosha processing can destabilize the transcript and reduces protein 
synthesis from it.  
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 Multiple non‑canonical pathways can feed pre‑miRNAs into the miRNA 
pathway through Drosha‑independent processes (Kim, et al., 2009). The biogenesis of a 
subset of microRNAs, mirtrons, has been found to depend on the splicing machinery 
rather than the Microprocessor. These small RNAs are embedded in introns of protein 
coding genes in flies and mammals. In humans the only real mirtron found so far is mir-
877. After splicing, the branch point of the lariat‑shaped intron is resolved and the 
debranched intron forms a hairpin structure that resembles pre-miRNA. With 
conventional mirtron loci, the resultant small RNAs begin and end precisely with splice 
donor and splice acceptor sites, being both ends of the pre-miRNA generated by the 
splicing reaction. However, in certain mirtron-like loci the small RNA-generating 
hairpin resides at one end of the intron, leaving and extended tail at either the 5′ or 3′ 
end which consequently requires exonucleolytic trimming to become a substrate for 
nuclear export. The majority of Drosha-independent miRNAs appear to be derived from 
long introns of protein-coding mRNAs, such as miR-342 or from independent 
transcriptional units, such as miR-320. This suggests that release of the pre-miRNA 
stem–loop intermediate requires a processing step rather than splicing alone. These 
Drosha-independent miRNAs tended to form these pre-miRNAs structures with 
extended stems of up to 65 nucleotides in length, instead of the 33 nucleotides of pre-
miRNAs originated from the canonical process (Kim, et al., 2009; Winter, et al., 2009; 
Chong, et al., 2010; Westholm and Lai, 2011).  
Some small nucleolar RNAs (snoRNAs), transfer RNAs (tRNAs), and 
endogenous short hairpin RNAs (shRNAs) are also processed into miRNA-like 
molecules independently of the Microprocessor complex. Deep sequencing efforts also 
reveal that endo-siRNA loci produce a distinct fraction of small RNAs that seem to load 
onto AGO1, and therefore might constitute functional miRNAs (Miyoshi, et al., 2010; 
Siomi and Siomi, 2010).  
 
I. 1.1.3 Transport to the cytoplasm 
The structure of pre-miRNAs, with marked signals of processing by Drosha is 
essential to their transport and further processing. The transport of these molecules to 
the cytoplasm is mediated by exportin 5 (EXP5), a member of the nuclear transport 
receptor family, that was mostly known as a transport factor for tRNAs, in a RAN-GTP-
dependent manner. EXP5 recognizes the dsRNA stem longer than 14 bp along with a 
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short 3′ overhang (1–8 nt) (Gregory and Shiekhattar, 2005; Kim, 2005; Krol, et al., 
2010).  
Interaction with EXP5 may stabilize pre-miRNAs, avoiding their degradation 
(Kim, 2005; Winter, et al., 2009). 
 
I.1.1.4 Processing by Dicer 
Once in the cytoplasm, the pre-miRNAs are cleaved near the terminal loop by 
Dicer, which measures ~22 nt from the pre‑existing terminus of the pre-miRNA, 
releasing a miRNA/miRNA* duplex.  
Dicer is highly conserved and present in almost all eukaryotic organisms and in 
some of them multiple Dicer isotypes with different roles have been found. Dicer is 
constituted by two RNase III domains, one dsRNA binding domain, a N’ terminal with 
a Dead box RNA helicase domain, a DUF283 domain and a PAZ domain (also present 
in AGO) that binds to the protruding end of small RNAs (Gregory and Shiekhattar, 
2005; Kim, 2005). Human Dicer interacts with TRBP (TAR RNA‑binding protein) and 
PACT (also known as PRKRA) which are not required for processing but they seem to 
contribute to the stability of miRNAs. Their biochemical roles remain to be established. 
TRBP functions as a negative regulator of dsRNA‑dependent protein kinase (PKR), 
whereas PACT stimulates it, but it is not clear at present, whether there is any functional 
connection between the miRNA pathway and PKR signaling (Kim, 2005; Kim, et al., 
2009; Krol, et al., 2010). 
Not all miRNAs require to be processed by Dicer. Although AGO2 does not 
need its catalytic domain active to exert its function, this domain is essential in 
erythropoiesis once pre-miR-451 has an unusual structure and cannot be recognized by 
Dicer. miR-451 is rendered active by AGO which cleaves its stem loop. This process is 
common to other miRNAs (Cheloufi et al., 2010; Miyoshi, et al., 2010). 
For miRNAs that have a high degree of complementarity along the hairpin stem, 
an additional endonucleolytic cleavage step occurs before Dicer mediated cleavage. The 
slicer activity of AGO2 cleaves the 3’ arm of the hairpin in the middle to generate a 
nicked hairpin. This precursor, called AGO-cleaved precursor miRNA (ac-pre-miRNA) 
facilitates subsequent strand dissociation and miRISC activation (Winter, et al., 2009). 
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In some cell lines, Drosha deficiency has a stronger impact than that of Dicer 
defiency, resulting therefore in different impacts in the canonical biogenesis pathway 
(Chong, et al., 2010). 
 
I.1.1.5 The miRISC complex 
In humans, Dicer, TRBP (and/or PACT) and AGO proteins form a RISC loading 
complex (RLC). The miRNA duplex is released from Dicer after cleavage and the stable 
end of the RNA duplex is bound to TRBP in the RLC, whereas the other end interacts 
with the AGO protein. After processing by Dicer, the duplex needs to be unwinded, 
however a universal helicase responsible for this process has not been identified yet. 
This means that different helicases may regulate different miRNAs and that they may 
not be generally required as in the case of ac-pre-miRNAs (Winter, et al., 2009). 
The mechanistic details of strand selection and RISC assembly have not been 
well delineated in humans. One strand of the RNA duplex remains in AGO as a mature 
miRNA (the guide strand or miRNA), to form the miRNA-containing RNA induced 
silencing complex (miRISC), whereas the other strand (the passenger strand or 
miRNA*) is thought to be degraded, but recent deep-sequencing efforts indicate that a 
large number of miRNA*s are not degraded and rather associate with AGO1 or AGO2. 
In most miRNA precursors the strand with thermodynamically relatively unstable base 
pairs at the 5′ end typically survives, for example, a GU pair compared with a GC pair. 
Once this is not a stringent process, some pre-miRNAs produce miRNAs from both 
strands at comparable frequencies. Although strand selection based on 5’ 
thermodynamic stability still contributes greatly to the sorting process, relative 
expression levels of the miRNA/miRNA* strands vary widely among tissues, indicating 
that strand selection factors other than sequence features might exist and that miRNA 
processing pathways are more complex than currently recognized (Kim, et al., 2009; 
Winter, et al., 2009; Siomi and Siomi, 2010). For example, the phosphorylated 5’ end of 
the miRNA guide strand seems to be critical for the interaction with the AGO proteins 
(Miyoshi, et al., 2010). 
The ends of miRNAs are often heterogeneous owing to either the addition or 
deletion of 1–2 nt. Sequence variations are found at both 5′ and 3′ ends where it pairs 
with target mRNAs and induce their translational repression or deadenylation and 
degradation. In some cases, miRNA repression can be reversed and the miRISC can 
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even activate expression of the target. How the miRISC represses or activates the 
expression of specific genes appears to be context-dependent and is the subject of 
ongoing debate (Miyoshi, et al., 2010). 
The mechanisms of the variations of the 5′ end are unknown, but they might be 
explained by imprecise or alternative processing by RNase III domains. Changes in the 
5′ terminus result in shifts of the seed sequences (2–7 nt from the 5′ end), which alter 
the target specificity of the miRNA.  
Paralogues often have identical sequences at seed sequence. The seed sequence 
is composed of 6 nucleotides and is crucial in base pairing with the target mRNA, the 
paralogues are thought to act redundantly. 3’ sequences of miRNAs also contribute to 
target binding and because the expression patterns of these sister miRNAs are often 
different from each other, members of the same seed family might have distinct roles in 
vivo. The 3′ end often contains untemplated nucleotides (mostly uracil and adenine), 
which must be added after processing by unknown terminal uridyl/adenyl transferases. 
Deletions of the 5′‑ and 3′‑end nucleotides are also often observed, which are probably 
due to exonucleolytic activities (Kim, et al., 2009).  
In Figure 2 we can observe most the steps of miRNA biogenesis that have been 
described so far. 
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Figure 2 miRNA biogenesis trough cananical and non-canonical pathways. Source: Krol, et al., 2010. 
 
I.1.1.6. Re-import of miRNAs into the nucleus 
Some mature miRNAs are mainly localized in the nucleus, such as miR-29b. 
These miRNAs have a hexanucleotidic terminal motif, a transferable nuclear 
localization element. The nuclear localization of a fraction of the subcellular AGO pool 
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in human cells is affected by RAN-GTP shuttle and Importin-8. Evidence is 
accumulating that miRNAs can regulate gene expression in the nucleus at the 
transcription level (Winter, et al., 2009). 
 
I.1.2. Regulation of miRNA biogenesis 
 
miRNAs are associated with most of the cellular processes, therefore its 
deregulation is often associated with human diseases, such as cancer. Deregulation of 
miRNA expression can result from impaired processing, copy number alteration of 
miRNA encoding loci or methylation of miRNA promoter region (Carleton, et al., 
2007).  
Transcription of miRNA genes is a major point of regulation in miRNA 
biogenesis, being regulated similarly to protein-coding genes. There are many Pol II-
associated transcription factors that are involved in transcriptional control of miRNA 
genes. Some miRNAs that are involved in the cell cycle progress and apoptosis are 
under the control of tumour‑suppressive or oncogenic transcription factors (Kim, et al., 
2009; Krol, et al., 2010).  
Control of gene expression by autoregulatory feedback loops is a regulatory 
mechanism that is particularly important during cell fate determination and 
development. miRNAs are uniquely suited to participate in feedback circuits due to 
their potential to directly base-pair with and repress mRNAs that encode factors 
involved in the biogenesis or function of the same miRNAs. Indeed, many examples 
have been described of miRNAs regulating their own transcription through single-
negative or double-negative (or positive) feedback loops with specific transcription 
factors. This coordinated expression might serve to prevent misexpression of cell-type-
specific miRNAs and to confer robustness to the underlying gene expression programs 
during development (Krol, et al., 2010; Siomi and Siomi, 2010). Some miRNAs are 
convergently transcribed from both DNA strands of a single locus, giving rise to two 
miRNAs with distinct seed sequences, therefore regulating different targets. miRNAs in 
the same genomic cluster can be transcribed and regulated independently (Winter, et al., 
2009). 
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Epigenetic control is also important to miRNA gene regulation. For example, the 
miR‑203 locus frequently undergoes DNA methylation in T‑cell lymphoma but not in 
normal T lymphocyte. 
Processing is another regulation point is especially important in defining the 
spatiotemporal pattern of miRNA expression. There is an unknown number of 
molecules that can stimulate or inhibit processing of certain miRNAs by Drosha, 
although the mechanisms are not clear yet. Recent works have identified a battery of 
proteins that regulate miRNAs processing (either positively or negatively) by 
interacting with Drosha, Dicer or by binding to miRNAs. Some auxiliary factors may 
function to promote the fidelity, specificity, and/ or activity of Drosha such as p68 
(DDX5) and p72 (DDX17) helicases, as well as heterogeneous nuclear 
ribonucleoproteins (hnRNPs) (Siomi and Siomi, 2010). KH-type splicing regulatory 
protein (KSRP) serves as a component of both Drosha and Dicer complexes and 
regulates the biogenesis of a subset of miRNAs, optimizing the positioning and or 
recruitment of both the miRNA precursor processing complexes through protein–
protein interactions. KSRP binds with high affinity to the terminal loop (TL) of the 
target miRNA precursors and promotes their maturation, remaining attached to the TL 
even during nucleo-cytoplasmic transition (Trabucchi, et al., 2009).  
Drosha and Dicer usually operate in complexes with double-stranded RBP 
partners, such as DGCR8 and TRBP in mammals. The levels and activity of all these 
proteins are subject to regulation that affects the accumulation of miRNAs. For 
example, DGCR8 has a stabilizing effect on Drosha through the interaction with its 
middle domain, whereas Drosha controls DGCR8 as described before. The Drosha to 
DGCR8 ratio is important, as a threefold excess of DGCR8 dramatically inhibits Drosha 
processing activity in vitro. Binding of an haem group to DGCR8 promotes its 
dimerization and facilitates pri-miRNA processing (Winter, et al., 2009; Krol, et al., 
2010). 
On the other hand, a decrease in TRBP leads to Dicer destabilization and pre-
miRNA processing defects. In human carcinomas, mutations causing diminished TRPB 
expression impair Dicer function. TRBP is stabilized through serine phosphorylation, 
catalysed by mitogen-activated protein kinase (MAPK)/extracellular regulated kinase 
(eRK). Dicer mRNA is targeted by let-7, forming a negative feedback loop influencing 
miRNA biogenesis, both physiologically and in cancer. Dicer’s amino-terminal helicase 
domain may have an autoregulatory function as its removal, or interaction with TRBP 
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stimulates catalytic activity of human Dicer. There is also evidence that proteolysis may 
play a role in modulating Dicer activity or even changing its specificity towards DNA 
(Krol, et al., 2010; Siomi and Siomi, 2010). 
The position of Drosha and Dicer cleavage determines the identity of 5’- 
terminal and/or 3’- terminal miRNA nucleotides. Notably, processing of some 
precursors by these enzymes is not regular and generates miRNA isoforms with 
different termini. Heterogeneity at the 5′ end in particular can have important functional 
consequences, as it affects the seed region consequently, changing the identity of 
targeted mRNAs. In addition, identity of the 5′-terminal nucleotide may also directly 
affect the efficiency of miRNA loading into miRISC, independent of the duplex end 
stability.  
Generally, most miRNA genes produce one dominant miRNA species. 
However, the ratio of miRNA to miRNA* can vary in different tissues or 
developmental stages, which probably depends on specific properties of the pre-miRNA 
or miRNA duplex, or on the activity of different accessory processing factors. 
Moreover, the ratio might be modulated by the availability of mRNA targets as a result 
of enhanced destabilization of either miRNA or miRNA* occurring in the absence of 
respective complementary mRNAs (Krol, et al., 2010). 
Although the final synthesis rate of a miRNA can, in principle, be controlled at 
any step of miRNA biogenesis, from transcription to mature miRNA turn over, recent 
findings have uncovered a significant role for post-transcriptional mechanisms in the 
regulation of miRNA biogenesis and activity (Siomi and Siomi, 2010). Post-
transcriptional regulation can be achieved through several processes and is unclear how 
many of such regulatory factors exist. It is plausible that nuclear RNA-binding proteins, 
influence miRNA processing through specific interactions with a subset of 
pri‑miRNAs. The LIN-28–let-7 regulatory system is a good example, once it is highly 
conserved in evolution and has an important role in maintaining the pluripotency of 
eSCs, and also in development and oncogenesis. If LIN-28 is expressed it represses the 
expression of mature let-7, thus contributing to a staminal phenotype and to the 
expression of several oncogenes, including MYC and K-RAS. 
Turnover of miRNAs is an unexplored area compared to biogenesis regulation, 
yet several examples of accelerated or regulated miRNAs turnover are known. RNA 
decay enzymes might target not only mature miRNAs but also their precursors 
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(pri‑miRNAs and pre‑miRNAs). Once bound to AGO proteins, mature miRNAs seem 
to be more stable than average mRNAs, however, certain miRNAs might be degraded 
much more rapidly than other miRNAs, which suggests that nucleases recognize 
miRNAs’ sequences. In mammals, these nucleases are still unknown (Kim, et al., 
2009). miRNA stability can be modulated by viral infection, although the mechanism 
remains unknown. Notably, some miRNAs turnover in neurons seems to be activity 
dependent, suggesting that active miRNAs metabolism may be important for neuronal 
function. The rapid turnover of miRNAs might be required for regulation of the newly 
synthesized mRNAs that are expressed in neurons, in response to their activation. 
Arsenite-resistance protein 2 (ARS2), a component of the nuclear cap-binding 
complex, interacts with Drosha and is required for pri-miRNA stability and processing 
in mammals. It seems to influence the processing of a subset of pri-miRNAs, having a 
regulatory rather than constitutive function. Several splicing factors also function as 
miRNAs processing regulators, independently from their role in splicing sometimes 
acting at both the Drosha and Dicer cleavage steps (Krol, et al., 2010; Siomi and Siomi, 
2010). 
RNA editing is another possible way of regulating miRNA biogenesis. The 
alteration of adenines to inosines in dsRNA segments, a process that is mediated by 
adenine deaminases (ADARs), has been observed in many pri- or pre-miRNAs. Since 
the modified pri‑miRNAs or pre‑miRNAs become poor substrates of Drosha and 
Dicer, editing of the precursor can interfere with miRNA processing. Editing can also 
change the target specificity of the miRNA if it occurs in miRNA seed sequences. This 
process is responsible as well for preventing the export of pre-miRNAs and for the 
degradation of some by nucleases. Nevertheless, editing of some miRNAs can enhance 
Drosha processing, underlying tissue-specific expression (Winter, et al., 2009). 
 
I.1.3. Regulation of miRNA function 
miRNAs effector pathway may be regulated at different levels. (Winter, et al, 
2009). 
They can control patterns of gene expression that occur during cell cycle 
progression, so the cell must have mechanisms that control their activity and it is 
possible that their stability and expression are altered during cell cycle. Controlling cell 
cycle, miRNAs act as buffers to limit the accumulation of many gene products that 
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impact cell cycle progression under a variety of complexes. Coordinate regulation of 
many targets may also allow for rapid reversal of miRNA –induced cell cycle regulation 
upon changes in miRNA synthesis, stability or location.  
miRNAs can also be controlled after biogenesis, especially at the level of 
miRISC components such as AGO proteins and GW182. 
Recent findings point to some distinct functions of individual AGOs in 
vertebrates. Different mammalian AGO proteins seem to differ in their potency to 
repress protein synthesis when binded to mRNAs. Hence, the relative abundance of 
individual AGO proteins may affect in a different manner the strength of miRNA 
repression in particular cells or tissues. 
miRNAs may differ on their intrinsic ability to be loaded into miRISC complex, 
therefore changes in cellular concentration of AGO proteins might have quantitative and 
qualitative effects on a range of miRNAs associated with miRISC. 
Several mechanisms that regulate AGO2 levels in mammalian cells have been 
described, including stabilization by the chaperone heat shock protein 90 (HSP90), 
modulating effects of protein modifications, such as polyubiquitylation promoted by 
TRIM-NHl, hydroxylation of Pro700 by type I collagen prolyl-4-hydroxylase C-P4H(I), 
phosphorylation on Ser387 in response to stress and mediated by the MAPK/p38 kinase 
signalling pathway. The last two modifications increase the localization of AGO2 to P-
bodies. The number and size of P-bodies is larger in proliferating cells compared to 
quiescent ones (Carleton, et al., 2007; Winter, et al., 2009; Krol, et al., 2010). 
On the other hand, TRIM32 enhance some miRNAs activity without changing 
their levels, being still unknown how TRIM32 enhance miRISC activity and whether it 
is able to bind RNA, either directly or through additional proteins. The specificity for 
only selected miRNAs could possibly arise from the recognition of unique features of 
the miRNA/mRNA duplex or selective enrichment of TRIM binding sites in the vicinity 
of sites recognized by a specific miRNA. Other TRIMs that polyubiquitylate AGO 
attenuate repression by miRNAs by proteasomal degradation of AGO2 (Krol, et al., 
2010). 
There are three GW182 paralogues in mammals (trinucleotide repeat-containing 
proteins TNRC6A, TNRC6B and TNRC6C) with multiple transcription start or splice 
variants. GW182 has an effector role on the repressive function of miRISC, as it 
interacts with and acts downstream of AGO, but little is yet known about their 
regulation. There is evidence that these proteins undergo modifications that modulate 
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their stability and function and they can also interact with many additional factors. 
Some of these factors have roles in translational repression or mRNA decay and some 
represent components of P-bodies, but so far the interaction mechanisms for most of the 
accessory proteins remains unknown. Moreover, their C-terminal segment, contains 
DUF RRM domains as well as sequences C-proximal to RRM as a minimal protein 
fragment, which effectively causes both translational repression and mRNA 
destabilization when tethered to the mRNA. Thereby, disruption of the GW182-AGO 
interaction, by point mutations or a peptide competing with GW182 for AGO binding, 
abrogates miRNA-mediated  repression (Fabian, et al., 2010). 
Many miRISC-interacting proteins belong to the family of DexD/H RNA 
helicases, which catalyze activities for miRISC assembly, binding to and dissociation 
from mRNA targets, or miRISC disassembly and turnover. Another group of factors 
attenuating or enhancing the effect of miRNAs are RBPs. Their association with 
miRISC components is often RNA-dependent, suggesting that they do not directly 
interact with miRISCs, but rather are recruited to the same targeted mRNA. The same 
RBP can, depending on the mRNA or cellular context, either prevent or activate 
miRISC repression. Not only could RBPs modulate miRISC effects, but miRISCs could 
also activate or repress RBP function by either competing for binding sites or blocking 
RBP activity by binding to them. 
The nuclear import receptor importin 8 (IMP8) associates with all four human 
AGO proteins independently of RNA, and localizes to the nucleus and P-bodies. IMP8 
is required for efficient binding of AGO2 to a large set of target mRNAs. 
miRNAs have been found to act not only as repressors but also act as activators 
of translation. Under conditions of serum starvation (or general growth arrest, or at the 
G0 stage) the AGO2-miRISC complex has been shown to switch from a translational 
repressor to an activator. This switch required fragile X-related protein 1 (FXR1). 
Considerable effort has been put into establishing whether components of 
miRISCs are associated with particular cellular structures and whether miRNA 
repression can be regulated at this level. P-bodies and stress granules have emerged as 
being potentially relevant to miRNA repression, as have multivesicular bodies (MVBs). 
Compartmentalization can control access to binding partners, concentrate factors that 
act together or temporarily segregate pathway components away from the rest of the 
cellular environment.  
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MVBs are specialized late-endosomal compartments, which contribute to 
miRNA function. Blocking MVB formation inhibits miRNA silencing, whereas 
blocking MVB turnover stimulates repression by miRNAs. The depletion of some 
endosomal sorting complex (ESCRT) factors leads to an increase in GW182 protein 
levels and an impaired loading of miRISC with small RNAs, suggesting that selective 
removal of GW182 from the miRISC, and its transit to MVBs, is important for the 
efficient formation of new miRISCs. Components of the miRISC loading complex had 
been found to be associated with membranous fractions in previous and mammalian 
AGO2 was initially characterized as a Golgi-associated or endoplasmic reticulum-
associated protein (Fabian, et al., 2010; Krol, et al., 2010). 
miRNAs can be transferred from cell to cell by exossomes or through immune 
synapses and can repress target genes in recipient cells. 
Although miRNA-mediated repression is considered to be a cytoplasmic event, 
substantial amounts of AGO2 and miRNAs have been found in the nuclei of different 
mammalian cell lines, and human GW182 protein TNRC6B has been shown to shuttle 
between the cytoplasm and the nucleus. It is yet unclear whether the nucleocytoplasmic 
shuttling of miRISC components is important for their cytoplasmic functions, or if it 
indicates that miRISCs have nuclear targets or perform nuclear function or functions 
unrelated to the established roles of miRNAs. Nevertheless miRNAs may play a role in 
transcriptional silencing in mammalian cells. 
 
I.1.4. Competing endogenous RNA (ceRNA) 
This new theory states that all types of RNA transcripts communicate through a 
new ‘‘language’’ mediated by miRNA-binding sites (‘‘miRNA response elements’’ – 
MREs). 
miRNAs bind to sequences with partial complementarity on target RNA 
transcripts, called microRNA response elements (MREs) being able to function in a 
combinatorial manner if a mRNA transcript harbors numerous MREs. Furthermore, 
each miRNA may repress up to hundreds of transcripts, and thus, it is estimated that 
microRNAs regulate a large proportion of the transcriptome. Once pseudogenes 
associated with one gene are widely conserved, it is possible that miRNAs can also 
target them, and as a matter of fact their expression displays tissue specificity and can 
be activated or silenced in specific pathological conditions, such as cancer. Therefore, 
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pseudogenes can act as miRNA competitors, competing with their ancestral protein-
coding genes for the same pool of miRNAs through sets of conserved MREs. 
Notably, microRNAs also regulate long noncoding RNAs (lncRNAs), which 
have been linked to epigenetic mechanisms, as shown in a recent global analysis of 
Argonaute (AGO)-bound transcripts. 
The consequence of competition for microRNAs is observed as a decrease in 
microRNA detection and thus an impairment of microRNA activity. On the basis of this 
hypothesis, MREs can be viewed as the letters of an ‘‘RNA language’’ by which 
transcripts can actively communicate to each other to regulate their respective 
expression levels. It is predicted that this ‘‘RNA language’’ can be used to functionalize 
the entire mRNA dimension through the identification of crosstalking ceRNAs, as well 
as ceRNA networks. This also challenges the notion that a protein-coding gene must be 
translated into a protein to exert function. Moreover, the noncoding function of mRNA 
may or may not be consistent with the coding function, thereby creating built-in 
regulatory loops, functional complexity, and diversification in both physiological and 
pathological conditions. 
Overall, ceRNA networks effectiveness depend on the identity, concentration, 
and subcellular distribution of the RNA and the miRNA species that are present in a 
tissue, developmental, or pathological context. The effectiveness of a ceRNA would 
depend on the number of miRNAs that it can ‘‘sponge’’. This, in turn, would depend on 
the ceRNA’s accessibility to miRNA molecules, which is influenced by its subcellular 
localization and its interaction with RBPs.  
Although two MREs may be predicted to bind the same microRNA, their 
specific nucleotide composition may be partially different, and the effectiveness of each 
MRE to bind a miRNA is critical for ceRNA function, so miRNAs are predicted not to 
exert the same degree of repression on all of them (Salmena, et al., 2011). 
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I.2. Tumourigenesis 
 
Tumourigenesis is the process of tumour development from a normal cell. 
Malignancy is the outcome of two successive events: cell transformation and tumour 
progression. Transformation could be defined as the autonomous proliferation of an 
immortal cell clone, whereas progression is the process which leads the immortal 
transformed clone to invasion and metastasis. Transformation involves a stepwise 
accumulation of genetic alterations, mainly chromosomal translocations and gene 
mutations, resulting in altered protein activity and/or expression of oncogenes and/or 
tumour suppressor genes which confer growth advantages to cancer cells leading to 
immortalization. Progression proceeds through continuing selection of the most 
advantageous clones from a genetically unstable population of transformed cells. 
Acquisition of malignancy is the result of tumour progression rather than 
transformation. During tumour progression, cancer cells lose their original shape and 
polarity and become more independent from neighboring tissues. Finally, they acquire 
the capacity to invade nearby tissues and metastasize to distant locations through the 
blood or lymphatic system.  
The tumour microenvironment plays an essential role in tumour progression as it 
is responsible in maintaining its differentiation state and in favoring the proliferation of 
cancer cells (Giannakakis, et al., 2007). 
Pathological analyses of a number of organs reveal lesions that appear to 
represent intermediate steps in a process through which cells evolve progressively from 
normalcy via a series of pre-malignant states into invasive cancers. 
These observations have been rendered more concrete by a large body of work 
indicating that the genomes of tumour cells are invariably altered at multiple sites, 
having suffered disruption through lesions as subtle as point mutations and as obvious 
as changes in chromosome complement. 
 Taken together observation of human cancers and animal models argue that 
tumour development proceeds via a succession of genetic changes, each conferring one 
or another type of growth advantage leads to the progressive conversion on normal 
human cells to cancer cells (Hanahan and Weinberg, 2000). 
However more recent studies have defined tumours as a group of cells which 
may exhibit different phenotypes and different differentiation stages. A sub-population 
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of cells shows both cancer properties and stem cell characteristics were named Cancer 
Stem Cells (CSC). CSCs might arise through neoplastic changes initiated in normal 
self-renewing stem cells or downstream progenitors with limited or no selfrenewal. 
Initial events in stem cells could cause expansion of the stem cell pool and/or   
expansion of downstream progenitors. Secondary events are more likely to occur in 
these expanded pools of target cells; thus, it is possible that transformation is initiated in 
a normal stem cell, but the final steps occur in downstream progenitors. The reactivation 
of a self-renewal program is a central feature of the oncogenic transformation of 
progenitors because these short-lived cells will otherwise die or undergo terminal 
differentiation before enough mutations occur for full neoplastic transformation. CSCs 
themselves might acquire additional genetic or epigenetic changes during tumour 
progression, and non-CSCs can acquire CSC-like properties through processes such as 
Epithelial–mesenchymal transition (EMT), leading to the evolution of tumour 
phenotype and intratumour heterogeneity (Wang, 2010).  
The hallmarks of cancer (Figure 3) are distinctive and complementary 
capabilities that enable allow cancer cells to survive, proliferate and disseminate 
growth, providing a solid foundation for understanding the biology of cancer. When 
they were first described, there were 6 fundamental characteristics considered: 
sustaining proliferative signaling, evading growth suppressors, enabling replicative 
immortality, activating invasion and metastasis, inducing angiogenesis and resisting cell 
death.  
In 2010 Hanahan and Weinberg suggested four other characteristics considered 
to be essential to most tumour induction and progression. Two of them, deregulating 
cellular genetics and avoiding immune destruction, are considered as emerging 
hallmarks because neither capability is yet generalized and fully validated. Additionally, 
two consequential characteristics of neoplasia facilitate acquisition of both core and 
emerging hallmarks: genomic instability endow cancer cells with genetic alterations that 
drive tumour progression; inflammation by innate immune cells can result in their 
inadvertent support of multiple hallmark capabilities, thereby manifesting the now 
widely appreciated tumour-promoting consequences of inflammatory responses 
(Hanahan and Weinberg, 2010). 
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Figure 3 - The hallmarks of cancer. Source: Hanahan and Weinberg, 2010. 
 
Arguably the most fundamental trait of cancer cells involves their ability to 
sustain chronic proliferation signaling in a number of alternative ways. They may 
produce growth factor ligands themselves, to which they can respond via the expression 
of cognate receptors, resulting in autocrine proliferative stimulation. Alternatively, 
cancer cells may send signals to stimulate normal cells within the supporting tumour-
associated stroma, which reciprocate by supplying the cancer cells with various growth 
factors. Receptor signaling can also be deregulated by elevating the levels of receptor 
proteins displayed at the cancer cell surface, rendering such cells hyperresponsive to 
otherwise-limiting amounts of growth factor ligand; the same outcome can result from 
structural alterations in the receptor molecules that facilitate ligand-independent firing. 
Growth factor independence may also derive from the constitutive activation of 
components of signaling pathways operating downstream of these receptors, obviating 
the need to stimulate these pathways by ligand-mediated receptor activation.  
Somatic mutations that activate additional downstream pathways and disruptions 
of negative-feedback mechanisms that attenuate proliferative signaling also contribute 
largely to the maintenance of this characteristic. 
In addition to the hallmark capability of inducing and sustaining positively 
acting growth-stimulatory signals, cancer cells must also circumvent powerful programs 
that negatively regulate cell proliferation. Many of these programs depend on the 
actions of tumour suppressor genes such as RB or TP53 that regulate cell cycle 
progression and apoptosis. The evasion of mechanisms of contact inhibition and 
corruption of the TGF-β pathway are also noteworthy to promote malignancy. 
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Programmed cell death by apoptosis serves as a natural barrier to cancer 
development. Elucidation of the signaling circuitry governing the apoptotic program has 
revealed how apoptosis is triggered in response to various physiologic stresses that 
cancer cells experience during the course of tumourigenesis or as a result of anticancer 
therapy. Notable among the apoptosis-inducing stresses are signaling imbalances 
resulting from elevated levels of oncogene signaling and DNA damage associated with 
hyperproliferation. Apoptosis is attenuated in those tumours that succeed in progressing 
to states of high-grade malignancy and resistance to therapy. In contrast to apoptosis, 
necrosis, has pro-inflammatory and tumour-promoting potential, as necrotic cell death 
releases pro-inflammatory signals into the surrounding tissue microenvironment. 
The immortalization of cells that proceed to form tumours has been attributed to 
their ability to maintain telomeric DNA at lengths sufficient to avoid triggering 
senescence or apoptosis, achieved most commonly by upregulating expression of 
telomerase or, less frequently, via an alternative recombination-based telomere 
maintenance mechanism. Hence, telomere shortening has come to be viewed as a 
clocking device that determines the limited replicative potential of normal cells and thus 
one that must be overcome by cancer cells. Moreover, cell senescence is emerging as a 
protective barrier to neoplastic expansion that can be triggered by various proliferation-
associated abnormalities, including high levels of oncogenic signaling and, apparently, 
subcritical shortening of telomeres. 
During tumour progression, an ‘‘angiogenic switch’’ is almost always activated 
and remains on, causing normally quiescent vasculature to continually sprout new 
vessels that help sustain expanding neoplastic growths. The angiogenic switch is 
governed by countervailing factors that either induce or oppose angiogenesis. Some of 
these angiogenic regulators are signaling proteins that bind to stimulatory or inhibitory 
cell surface receptors displayed by vascular endothelial cells. The well-known 
prototypes of angiogenesis inducers and inhibitors are vascular endothelial growth 
factor-A (VEGF-A) and thrombospondin-1 (TSP-1), respectively.  
Tumour neovasculature is marked by precocious capillary sprouting, convoluted 
and excessive vessel branching, distorted and enlarged vessels, erratic blood flow, 
microhemorrhaging, leakiness, and abnormal levels of endothelial cell proliferation and 
apoptosis. Not all tumours maintain the same level of activation of angiogenesis, 
thereby resulting in different levels of vascularization.  
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The capacity to invade and metastatize to other tissues is essential to tumour 
progression. The multistep process of invasion and metastasis has been schematized as a 
sequence of discrete steps. This depiction envisions a succession of cell-biologic 
changes, beginning with loss of cell-cell and cell-matrix adhesion, migration or local 
invasion, then intravasation by cancer cells into nearby blood and lymphatic vessels, 
transit of cancer cells through the lymphatic and hematogenous systems, followed by 
escape of cancer cells from the lumina of such vessels into the parenchyma of distant 
tissues (extravasation), the formation of small nodules of cancer cells 
(micrometastases), and finally the growth of micrometastatic lesions into macroscopic 
tumours (colonization). In some types of cancer, the primary tumour may release 
systemic suppressor factors that render micrometastases dormant. Micrometastases may 
lack some hallmark capabilities necessary for vigorous growth, such as the ability to 
activate angiogenesis. 
Invasion seems to be facilitated by inflammatory cells that assemble at the 
boundaries of tumours, producing the extracellular matrix-degrading enzymes and other 
factors that enable invasive growth (Hanahan and Weinberg, 2010). 
Tumour cells have a metabolism that is remarkably different from that in normal 
differentiated cells. Transformed cells take up and metabolize nutrients such as glucose 
and glutamine at high levels that support anabolic growth. In contrast to normal 
differentiated cells that rely primarily on mitochondrial oxidative phosphorylation to 
generate energy needed for cellular processes, most cancer cells instead depend on 
aerobic glycolysis, a phenomenon termed ‘‘the Warburg effect’’. The metabolic 
alterations and adaptations of cancer cells create a phenotype that is essential for tumour 
cell growth and survival, altering flux along key metabolic pathways such as glycolysis 
and glutaminolysis. Indeed there is mounting evidence for the therapeutic potential of 
targeting cancer metabolic reprogramming (Garcia-Cao, et al., 2012). 
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I.2.1. miRNAs and tumourigenesis 
Studies in the past few years have established miRNAs as important molecules 
in the pathogenesis of various solid tumours, suggesting their possible role and 
utilization in cancer screening, treatment and prediction of outcome (Torres, et al., 
2011). 
miRNAs are frequently located at genomic regions involved in cancers and their 
regulatory function, such as chromosomes hot-spots, and are able to modulate 
oncogenic molecular networks by activating oncogenes and inactivating tumour 
suppressor genes, as can be seen in Figure 4 (Gregory and Shiekhattar, 2005). These 
alterations contribute to the loss of cell cycle control and increased proliferative 
capacity, characteristics of transformed cells. They can also contribute to the less 
differentiated state of tumours and can act simultaneously as apoptosis and checkpoint 
regulators directly or indirectly, regulating different targets. 
 
 
 
Figure 4 - miRNA involvement in oncogenic transformation. (a) miRNAs act as tumour suppressors 
when they target oncogenes. Any deregulation in their processing may lead to the non regulation of these 
targets and thereby to the increased expression of oncogenes, increasing the levels of their respective proteins. 
(b) miRNAs act as oncogenes when they target tumour suppressor genes due to copy number alteration and 
other processes. Like this, miRNAs inhibit their expression and the levels of the respective proteins are 
negatively modulated. Source: Ferracin and Negrini, 2012. 
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Altered miRNA expression leads to altered regulation of target mRNAs which is 
important in tumourigenesis. The impact of miRNA sequence variation is a result of cell 
type–specific expression levels of both miRNAs and their targets: cell type–specific 
transcriptomes. In addition, it is important to note that tumourigenesis-related 
alterations in a cell's transcriptome may also affect the regulatory capacity of miRNAs 
to the extent that a miRNA variant allele may have a protective effect for disease, as 
well as predict poor prognosis (Christensen, et al., 2010). 
Tumours may exhibit global decrease in levels of mature miRNAs due to failure 
of Drosha. Global repression of miRNAs processing can promote tumourigenesis and 
cell cycle entry in part by relieving constraints on the activity of known oncogenes. 
Deletion of certain miRNAs loci in different tumour types and correlation of miRNA 
deletion with poor clinical prognosis has led to the prediction that miRNAs act as 
tumour suppressors (Carleton, et al., 2007; Siomi and Siomi, 2010). An interesting fact 
is that in patients with cancer, the loss of Drosha expression is correlated with the body 
mass index (BMI), decreasing with the increase of this factor. This is also associated 
with a greater invasion and metastatic potential and a worse prognosis. However data 
present in literature is inconsistent. 
Proteins p53, p63 and p73 regulate processing components of miRNAs including 
Drosha and Dicer through specific miRNAs (Torres, et al., 2011). 
Low amounts of Dicer1 mRNA are associated with a poor prognosis in lung and 
advanced breast cancer (Siomi and Siomi, 2010; Bahubeshi, et al., 2011). 
The expression of Dicer1 and Drosha affects differently diverse tumours and 
different tumour stages. This means that there is a tissue specific effect associated with 
aberrant expression patterns of miRNA pathway genes and that the effects of an 
aberration in the miRNA processing pathway on cancer initiation and progression are 
complex. Non-consistent pattern emerge with conflicting data arising from different 
studies. Nevertheless, it is clear that the miRNA processing pathway plays a crucial role 
in the initiation and progression of many cancer types. 
Many miRNAs sequence aberrations found in tumours alter the secondary 
structure without affecting processing and reveal the structural flexibility of the 
Microprocessor complex (Winter, et al., 2009). Even though a minority of miRNAs 
may be deregulated in a wide range of tumours, most of them are cancer-type specific. 
In solid tumours, it appears as the most common miRNA event is gain of expression, 
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whereas loss of expression in cancer is a more limited event and more tissue specific 
(Volinia, et al., 2006). 
miRNA expression patterns appear to be more reliable than mRNA expression 
patterns and possess a greater resolution analysis: they can successfully identify 
different subtypes and predict the biologic and clinical behavior of a cancer type. 
Plasma miRNAs have already been referred to as potential biomarkers for non-
invasive diagnostics and prognosis, being possibly able to regulate expression in other 
cells (Figure 5). There have also been described miRNAs contained in exosomes in 
other human fluids, such as saliva or urine, which have an altered concentration in 
diverse human pathologies and thus can be useful in detecting and distinguishing 
different diseases in a non-invasive way. miRNAs can also associate with other 
biomolecules, such as lipids, to achieve improved nuclease resistance. This suggests 
that some cell-free miRNAs carry regulatory signals between widely separated organs 
to regulate functions.  
 
Figure 5 - miRNAs may be transported by exossomes from cell to cell. Source: Stoorvogel, 2012. 
miRNAs and their processing machinery could be possible important targets for 
therapy. The delivery of miRNAs to selected tumour sites may require novel delivery 
systems such as the polyethylenimine-based nanoparticles that were recently reported to 
be effective carriers in a mouse model of colon cancer (Bahubeshi, et al., 2011; Liu, et 
al., 2012; Pant, et al., 2012). 
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I.3. PI3K/AKT Pathway 
 
Since its discovery in the 1980s, the family of lipid kinases termed 
phosphoinositide 3- kinases (PI3Ks) has been found to play key regulatory roles in 
many cellular processes including cell survival, proliferation and differentiation. PI3Ks 
have been divided into three classes according to their structural characteristics and 
substrate specificity. The most commonly studied are the class I enzymes that are 
activated directly by cell surface receptors. Class I PI3Ks are further divided into class 
IA enzymes, activated by receptors of tyrosine-kinases (RTKs), G protein-coupled 
receptors (GPCRs) and certain oncogenes such as the small G protein Ras, and class IB 
enzymes, regulated exclusively by GPCRs (Liu, et al., 2009). 
PI3K catalyzes the production of the lipid second messenger 
phosphatidylinositol-3,4,5-triphosphate (PIP3) at the cell membrane. PIP3 in turn 
contributes to the recruitment and activation of a wide range of downstream targets, 
including the serine-threonine protein kinase AKT multi-gene family (AKT-1, AKT-2 
and AKT-3, also known as protein kinase B – PKB). The PI3K-AKT signaling pathway 
(Figure 6) regulates many normal cellular processes including cell proliferation, 
survival, growth, and motility processes that are critical for tumourigenesis. Indeed, the 
role of this pathway in oncogenesis has been extensively investigated and altered 
expression or mutation of many components of this pathway have been implicated in 
human cancer (Luo, et al., 2003; McCubrey, et al., 2008).  
Both growth factor RTKs and GPCRs can activate PI3K signaling, however the 
first has been better described and has a clear role in human pathologies. The binding of 
Insulin-like growth factor 1 (IGF-1) to its receptor triggers the activation of several 
intracellular kinases, including PI3K (Stitt, et al., 2004). 
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Figure 6 - The PI3K-AKT pathway. Source: [5] 
Growth factor RTKs engage the class-Ia PI3K, which is a heterodimer 
comprised of the p85 regulatory and p110 catalytic subunits. The p85 regulatory subunit 
contains Src-homology 2 (SH2) domains, that recognize phosphorylated (p) Y (pY) 
residues, an iSH2 domain (a rigid tether for p110), a conserved domain related to 
sequences present in the Break Point Cluster Region (BCR) gene and a SH3 domain 
which is found in proteins that interact with other proteins and mediate assembly of 
specific protein complexes via binding to proline-rich motifs. Specific phospho-tyrosine 
residues on the activated receptor or on associated adaptor proteins bind the SH2 
domains of p85 and recruit the enzyme to the membrane.  
The 110-kDA PI3K Class 1A catalytic subunit contains a p85 binding domain, a 
Ras binding domain, a kinase domain and an helical domain. Cytokine stimulation often 
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creates a PI3K binding site on the cytokine receptor. The p85 subunit SH2 domain 
associates with this site. The p85 subunit is then phosphorylated leading to activation of  
the p110 catalytic subunit. This often occurs at the inner leaflet of the cytoplasmic 
membrane, although there are important roles of PI3K in the nuclear membranes which 
have been registered (McCubrey, et al., 2008; Liu, et al., 2009). 
In the membrane, PI3K phosphorylates phosphatidylinositol-4,5-bisphosphate 
(PIP2) converting PIP2 to PIP3. Subsequently, PIP3 recruits other downstream 
molecules, site particularly the serine-threonine kinases AKT and PDK1 via binding to 
their pleckstrin homology (PH) domains and creates a lipid binding for them in the 
membrane (Stitt, et al., 2004). 
At the membrane, AKT is partially activated through phosphorylation in its 
activation loop by PDK1. Depending on the AKT isoform, PDK1 can phosphorylate 
AKT on T308/T309/T305. A second kinase, mostly mTORC2, phosphorylates AKT on 
a S regulatory residue (S473/S474/S472) in the C terminus of AKT, resulting in its full 
activation. AKT in turn has been postulated to phosphorylate over 9000 proteins, 
controlling cell proliferation, survival, growth, and other processes. The PH domain 
leucine-rich repeat protein phosphatase (PHLPP) dephosphorylates S473 on AKT 
inducing apoptosis and inhibiting tumour growth (Luo, et al., 2003; McCubrey, et al., 
2008; Bozulic and Hemmings, 2009; Liu, et al., 2009). 
 The levels of PIP3 in the cell are strictly regulated and several lipid 
phosphatases act to rapidly remove it.  Of particular interest is the 3’- phosphatase 
PTEN (phosphatase and tensin homolog deleted on chromosome ten), which converts 
PIP3 back to PIP2, preventing AKT activation and has become known as a major 
tumour suppressor in different tissues. Two other phosphatases, SH2 domain-containing 
inositol 5’phosphatase (SHIP)-1 and SHIP-2, also dephosphorilate PIP3 to PIP2. 
Mutations in these phosphatases, which eliminate their activity, can lead to tumour 
progression. Consequently, the genes encoding these phosphatases are referred to as 
anti-oncogenes or tumour suppressor genes (Luo, et al., 2003; McCubrey, et al., 2008). 
Aberrant activation of the PI3K-AKT pathway has been widely implicated in 
many cancers. Gene amplification of p110 occurs in some cases of human ovarian 
cancer, and amplification of AKT is found in ovarian, breast, and colon cancer.  
Hyperactivation of the PI3K-AKT pathway allows cancer cells to improve 
proliferation and survival and is now evident that is also coinvolved in cell hypertrophy, 
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which are important processes for neoplastic progression (Stitt, et al., 2004; McCubrey, 
et al., 2008).  
The PI3K-AKT pathway is a key regulator of cell survival through multiple 
downstream targets. The FOXO proteins, a subgroup of the Forkhead family of 
transcription factors are known to mediate apoptosis by activating the transcription of 
proapoptotic genes such as FasL and Bim, and to regulate genes involved in metabolism 
and cell cycle progression. Phosphorylation of the FOXO transcription factors on 
multiple sites by AKT leads to citoplasmic retention of phosphorylated FOXO proteins 
and inhibition of their transcriptional functions (Luo, et al., 2003; Stitt, et al., 2004). 
Similarly, AKT can phosphorylate the proapoptotic Bcl-2 family member Bad, causing 
its sequestration from the mitochondrial membrane. 
There may be a reciprocal regulation between the PI3K-AKT pathway and the 
tumour suppressor protein p53, since PTEN is a transcriptional target of p53 and AKT 
can promote p53 degradation by phosphorylating and activating its negative regulator 
Mdm2. Consequently, there is a major inhibition of apoptosis. 
The PI3K-AKT pathway, in parallel to the Ras/MAPK pathway, contributes to 
the regulation of cell cycle progression, particularly at the G1/S transition. The kinase 
GSK3 phosphorylates and promotes the degradation of cyclin D1 and Myc, two proteins 
that drive S phase entry. AKT phosphorylates and inhibits GSK3, thereby contributing 
to the stabilization of cyclin D1 and Myc. The FOXO transcription factors repress 
cyclin D1 expression while enhancing expression of the cell cycle inhibitors p27
kip1
 and 
p130Rb2 and are themselves inactivated by AKT-mediated phosphorylation, conferring 
a proliferative vantage to cancer cells. 
In response to both nutrient availability and mitogenic growth factors, the 
mammalian target of rapamycin (mTOR) can control cell growth. In mammalian cells, 
mTOR exists in at least two complexes of distinct structure, physiology and substrate 
specificity. Rapamycin-sensitive mTOR complex 1 (mTORC1) is defined by the 
presence of Raptor (Regulatory associated protein of mTOR). Activation of mTORC1 
involves PI3-kinase-dependent activation of AKT and tuberous sclerosis (TSC) protein 
phosphorylation. 4E-BP1, p70S6K and PRAS40 are all substrates of mTORC1. On the 
contrary, Rictor (rapamycin-insensitive companion of mTOR), mSin1 and Protor mark 
the mTOR complex 2 (mTORC2), which is active in a PKCα-dependent manner. The 
main substrate of mTORC2 described to date is AKT. Thus, mTOR in the complex 
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mTORC2 acts as an AKT activator, whilst complex mTORC1 receives stimulatory 
input from AKT (Bozulic and Hemmings, 2009). 
mTORC1 stimulate protein translation by activating the 70 kDa ribosomal S6 
kinase (S6K1) and inhibiting the elongation-initiation factor 4E binding protein-1 (4E-
BP1). Integration of a variety of signals (mitogens, growth factors, and hormones) by 
mTOR assures cell cycle entry only if nutrients and energy are sufficient for cell 
duplication. Consequently, mTOR controls multiple steps involved in protein synthesis, 
but importantly enhances production of key molecules such as c-Myc, cyclin D1, 
p27Kip1, and retinoblastoma protein (pRb). mTOR also controls the translation of 
hypoxia-inducible transcription factor-1a (HIF-1a) mRNA. HIF-1a upregulation leads to 
an increased expression of angiogenic factors such as vascular endothelial growth factor 
(VEGF) and platelet-derived growth factor (PDGF). Moreover, HIF-1a regulates the 
glycolytic pathway by controlling the expression of glucose-sensing molecules 
including glucose transporter (Glut) 1 and Glut3 (Luo, et al., 2003). 
AKT-mediated regulation of mTOR activity is a complex multi-step 
phenomenon. AKT inhibits tuberous sclerosis 2 (TSC2) function through direct 
phosphorylation. TSC2 is a GTPase-activating protein (GAP) that functions in 
association with the putative tuberous sclerosis 1 (TSC1) to inactivate the small GTPase 
protein Rheb (Ras homolog enriched in brain). TSC2 phosphorylation by AKT 
represses GAP activity of the TSC1/TSC2 complex, allowing Rheb to accumulate in a 
GTP-bound state. Rheb-GTP then activates, the protein kinase activity of mTOR when 
complexed with Raptor protein and mLST8, a member of the Lethal-with-Sec-Thirteen 
gene family. The mTOR/Raptor/mLST8 complex (mTORC1) is sensitive to rapamycin 
and inhibits AKT via a negative feedback loop which involves, at least in part, p70S6K 
(Foster, et al., 2010; Goncharova, et al., 2011).   
The relationship between AKT and mTOR is further complicated by the 
existence of the mTORC2, which displays rapamycinin sensitive activity. The 
mTORC2 complex directly phosphorylates AKT on S473 in vitro and facilitates T308 
phosphorylation. AKT and mTOR are linked to each other via ill-defined positive and 
negative regulatory circuits, which restrain their simultaneous hyperactivation through a 
mechanism involving p70S6K and PI3K. Assuming that the equilibrium exists between 
these two complexes within the cell, when the mTORC1 complex is formed, it could 
antagonize the formation of the mTORC2 complex and reduce AKT activity. Thus, at 
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least in principle, inhibition of the mTORC1 complex could result in AKT 
hyperactivation.  
Furthermore, this PI3K-AKT-TSC-mTOR branch is emerging as a critical 
contributor to the oncogenic properties of the PI3K-AKT pathway. 
PI3K may contribute to other aspects of tumourigenesis in both AKT-dependent 
and -independent manners. PIP3 regulates the small GTPase Rac by activating a subset 
of its GTP-GDP exchange factors. Since Rac controls rearrangement of the actin 
cytoskeleton and cell motility and is important for Ras-mediated transformation, PI3K 
might activate both Rac- and Ras-dependent invasion events that contribute to 
metastasis. In addition, the PI3K-AKT pathway may also contribute to tumour 
angiogenesis. 
Components of the PI3K-AKT pathway present promising targets for therapeutic 
intervention for several reasons. This pathway inhibits many “tumour suppressor-like” 
proteins such as the FOXO transcription factors, Bad, GSK3 that negatively regulate 
cell survival, proliferation, and growth. Blocking this pathway could therefore 
simultaneously inhibit the proliferation of tumour cells and sensitize them toward 
apoptosis. Second, many components in the PI3K-AKT pathway are kinases, one of the 
most “druggable” classes of intracellular targets, ideal for the development of small 
molecule inhibitors. Third, as hyperactivation of the PI3K-AKT pathway is found in a 
wide range of tumours, drugs inhibiting this pathway are likely to have broad 
applications for treating different types of cancer. 
Because only a subset of the cellular processes regulated by the PI3K-AKT 
pathway are involved in tumourigenesis, the choice of drug targets must take into 
account the adverse effects resulting from the inhibition of other PI3K-AKT-dependent 
cellular processes. For example, insulin’s effects on metabolism are mediated through 
the PI3K-AKT pathway and inhibitors are therefore likely to perturb glucose 
homeostasis.  
A reasonable therapeutic index would depend on tumours being more sensitive 
to inhibitors of this pathway than normal tissues. The prevalence of a hyperactivated 
PI3K-AKT pathway in human cancers indicates this may indeed be the case, and a 
partial inhibition of this pathway might be sufficient to inhibit tumour growth while 
sparing normal cells (Luo, et al., 2003). 
Very recent studies showed PTEN as a key node for the control of obesity and 
tumourigenesis. Mice overexpressing PTEN exhibit an unexpected cancer-resistant and 
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unique metabolic state, which is the outcome of the ability of PTEN to regulate 
metabolism at multiple levels both from the cytosol and from the nucleus. On the one 
hand, these mice exhibit increased oxygen consumption and energy expenditure. On the 
other hand, mice and cells are less prone to transformation and cancer development. 
Thus, the features observed resemble an ‘‘anti-Warburg state’’, in which less glucose is 
taken up but is more efficiently directed to the mitochondrial tricarboxylic acid cycle. 
Moreover, PTEN elevations induce mitochondrial biogenesis and thus increased 
mitochondrial ATP production. Thus PTEN couples mitochondrial function and 
dynamics to cellular metabolism through PI3K-dependent and PI3K-independent 
mechanisms.  
PTEN elevation hence represents a potentially attractive therapeutic approach 
that could both prevent cancer development and increase energy expenditure to oppose 
fat accumulation and obesity (Garcia-Cao, et al., 2012).  
I.5. Lung Cancer 
 
Cancer is the leading cause of death in economically developed countries and 
the second leading cause of death in developing countries. The burden of cancer is 
increasing in economically developing countries as a result of population aging and 
growth as well as, increasingly, an adoption of cancer-associated lifestyle choices 
including smoking, physical inactivity, and ‘‘westernized’’ diets. Breast cancer in 
females and lung cancer in males are the most frequently diagnosed cancers and the 
leading cause of cancer death for each sex in both economically developed and 
developing countries, except lung cancer is preceded by prostate cancer as the most 
frequent cancer among males in economically developed countries.  
Lung cancer was the most commonly diagnosed cancer as well as the leading 
cause of cancer death in males in 2008 globally. Among females, it was the fourth most 
commonly diagnosed cancer and the second leading cause of cancer death. Lung cancer 
accounts for 13% (1.6 million) of the total cases and 18% (1.4 million) of the deaths in 
2008 (Jemal, et al., 2011).  
The observed variations in lung cancer rates and trends across countries or 
between males and females within each country largely reflect differences in the stage 
and degree of the tobacco consume. Smoking accounts for 80% of the worldwide lung 
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cancer burden in males and at least 50% of the burden in females. Male lung cancer 
death rates are decreasing in most Western countries, where the tobacco epidemic 
peaked by the middle of the last century. In contrast, lung cancer rates are increasing in 
several countries in Asia and Africa, where the epidemic has been established more 
recently and smoking prevalence continues to either increase or show signs of stability.  
Generally, lung cancer trends among females lag behind males because females 
started smoking in large numbers several decades later than males (Jemal, et al., 2011). 
Based on pathologic features, lung cancers are classified into non-small cell lung 
cancer (NSCLC), which accounts for about 85% of cases, and small cell lung cancer 
(SCLC) that accounts for approximately 15% of cases. NSCLC is divided into three 
major histologic subtypes, adenocarcinoma, squamous cell carcinoma (SCC) and large 
cell carcinoma (a poorly differentiated subtype usually diagnosed by exclusion of the 
other three types of lung cancer). SCC used to be the most common histologic subtype 
of NSCLC, however, in recent years there has been a significant increase in the 
proportion of adenocarcinoma cases with a corresponding decline in proportion of SCC 
cases. On the one hand, squamous and small cell tumours are thought to derive mainly 
from epithelial cells that line the larger airways. On the other hand, adenocarcinomas 
and large cell carcinomas, are thought to derive from epithelial cells that line the 
peripheral small airways (Garber, et al., 2001; Kotsakis, et al., 2010). 
Patients with lung cancer present with progressive shortness of breath, cough, 
chest pain/oppression, hoarseness or loss of voice. Pneumonia (often recidivant) is the 
presenting feature in many patients. Relative to other forms of non small cell lung 
cancer, adenocarcinoma is more often asymptomatic, being more frequently identified 
in screening studies or as an incidental radiologic finding. Patients with small SCLC 
often present symptoms referable to distant metastases (Travis, et al., 1999). 
NSCLC cases cases frequently diagnosed at advanced stages, resulting in an 
overall 5-year survival rates are: 56% for stage I, 34% for stage II, 10% for stage III, 
and 2% for stage IV. Conversely, the 5-year survival rate in stage I NSCLC patients 
who have received effective treatments can be as high as 83%. Therefore, finding 
NSCLC earlier may reduce the mortality (Clements, et al., 2010; Shen, et al., 2011). 
Patients with nonsmall cell lung tumours are treated differently from those with 
small cell tumours. The pathological distinction between small SCLC and NSCLC is, 
therefore, very important.  
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There is relative consensus among pathologyists on the diagnosis of SCLC. 
These tumours progress along a typical clinical course that is characterized by an 
excellent initial response to chemotherapy and is often associated with several months 
of complete regression. This short-term regression is followed by recurrence, 
development of chemo-resistance, and finally death caused by systemic dissemination.  
In contrast, the morphological subtyping of NSCLC is more difficult and far less 
reliable in predicting patient outcome. Approximately 50% of patients die from 
metastatic disease even after complete surgical removal of the primary tumour. The 
initial tumour pathologic diagnosis is based on small bronchoscopic biopsy specimens 
and may change when surgically removed specimens are re-examined.  
Lung tumour heterogeneity is well documented and is reflected in the 
morphological classification of mixed tumours such as adenosquamous carcinoma or 
combined SCLC containing both small cell and non-small cell components (Garber, et 
al., 2001). 
The diagnostic tests available to date are mainly invasive, thereby it is important 
to develop a reliable non-invasive strategy, taking advantage of recent developments in 
molecular genetics for diagnosis of early stage NSCLC. 
Numerous tumour-specific molecular alterations have been identified in 
plasma/serum and shown the potential as biomarkers in patients with lung cancers. 
However, none of the tested markers thus far had sufficiently achieved the required 
characteristics for diagnosis of NSCLC. miRNAs present in plasma possess 
considerable resistance to the enzymatic cleavage of RNase A and a panel of plasma 
miRNAs would provide potential biomarkers that could differentiate NSCLC patients 
from healthy individuals and among them (adenocarcinoma and squamous cell 
carcinoma (Lin, et al., 2010; Shen, et al., 2011). 
I.4.1. miRNAs in lung cancer 
There are several reports that show the co-involvement of miRNAs in different 
stages of lung cancer, and in this subsection are presented some examples of how 
miRNAs have been found to regulate mechanisms linked to lung cancer and especially 
to non-small cell lung cancer (NSCLC) . 
Accumulating evidence shows that miRNAs are grossly deregulated in NSCLC. 
Recent studies have shown that not only can miRNAs be used to sub-classify NSCLCs 
but specific miRNA profiles may also predict prognosis and disease recurrence in early-
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stage NSCLCs (Lin, et al., 2010). An inherited single nucleotidic polymorphism (SNP) 
in Drosha’s gene (RNASEN) has been shown to be associated with a differential 
prognosis and overall survival in patients with this malignancy (Rotunno, et al., 2010). 
There are a number of miRNAs that have already been successfully associated 
with lung cancer. For example, the let-7 family is a cluster of miRNAs whose genes 
map to different chromosomal regions that are frequently deleted in lung cancer. 
Thereby, its down-regulation is associated with poor prognosis, especially in NSCLC 
patients, and a single nucleotide polymorphism in let-7 complementary site 6 of the K-
RAS mRNA 3’-UTR is significantly associated with increased risk for NSCLC among 
moderate smokers. 
All members of the miR-17-29 cluster cooperate with c-Myc to accelerate 
tumour development and help promote tumour neovascularisation. The miR-17-92 
cluster is overexpressed in small-cell lung cancer (Lin, et al., 2010; Wang, et al., 2010). 
miRNAs may also be involved in chemo-sensitivity/-resistance determination,  
suggesting the possibility that manipulating miRNAs may be potentially useful to 
modulate the cancer chemoresistance. As a matter of example, miR-221 and miR-222 
contribute to lung cancer resistance to TRAIL (Tumour necrosis factor-Related 
Apoptosis Inducing Ligand) therapy by downregulating the tumour suppressors PTEN 
and TIMP3.  
Epidermal growth factor receptor (EGFR) is one of the most common proto-
oncogenes in lung cancer and the expression of some miRNAs is altered and directly 
linked to this pathway. For example, miR-21 is upregulated under conditions in which 
EGFR signalling is activated, especially in the context of EGFR-activating mutations, 
and is suggested to be related to lung carcinogenesis in non-smokers (Lin, et al., 2010). 
The miRNAs predicted to have a major oncogenic potential in lung cancer, and 
that are associated with a worse prognosis are the following: miR-17-92, miR-21, miR-
27, miR-93, miR-106, miR-128, miR-155, miR-181, miR-196, miR-199, miR-210, 
miR-214 and miR-301. Wang et al. (2010), also identified some miRNAs that are 
down-regulated in the lungs of rats exposed to cigarette smoke, those being: let-7, miR-
10, miR-26, miR-30, miR-34, miR-99, miR-122, miR-123, miR-124, miR-125, miR-
140, miR-145, miR-146, miR-191, miR-192, miR-219, miR-222 and miR-223. 
Furthermore, the stoichiometry of miRNA machinery and RISC depends on 
histologic subtype of lung carcinoma and varies along the atypical adenomatous 
hyperplasia-bronchoalveolar carcinomas (AAH-BAC), adenocarcinoma sequence. Dicer 
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is up-regulated in AAH and BAC and down-regulated in areas of invasion and in 
advanced adenocarcinoma. Higher Dicer level in SCLC is found when compared with 
adenocarcinoma. 
In conclusion, miRNAs can regulate autocrine/paracrine loops, anti-apoptotic 
genes, genes that promote tumour vasculature development, cell cycle related genes, 
metastasis related genes and chemoresistance genes in lung tissue, contributing grately 
to the initiation and progression of lung cancer (Wang, et al., 2010). 
 
I.5. hsa-miR-196a 
 
In a generic manner, miR-196 seems to be conserved only in vertebrates. miR-
196 is encoded at 3 paralogous locations in the A, B, and C mammalian HOX clusters, 
with miR196a1 in an intergenic region at the HOXB cluster on chromosome 17q21-q22, 
miR196a2 at the HOXC cluster on 12q13, and miR196b at the HOXA cluster on 7p15-
p14.2 [1,2,3]. HOX proteins are major transcription factors that play a crucial role 
during embryogenesis, organogenesis and diverse oncogenic malignancies. 
 
Figure 7 - Cytogenetic localization of hsa-miR-196a1. Source: [6] 
 
miR-196 family members may be influenced by regulatory controls imposed on 
the HOX cluster, but this regulation by control elements is not simply shared with the 
nearest HOX gene, as they can target HOX genes. For example, miR-196a1 targets 
HOXb8 3’ UTR with a high complementarity level. The perfect complementarity 
between miR-196a1 and the HOXb8 3’ UTR suggests that miR-196a1 can mediate 
degradation rather than translational repression of HOXb8 mRNA (Mansfield, et al., 
2004). These results indicate a miRNA-mediated regulation of HOX gene expression 
during vertebrate embryogenesis (Schimanski, et al., 2009). 
A variety of reports identified miR-196a as a potential biomarker, which was 
associated with multiple kinds of malignant tumours. According to this data, this 
miRNA has been reported to be highly expressed in human breast cancer and might be 
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related to the survival of patients with pancreatic adenocarcinoma. Additionally, miR-
196a was believed to participate in the regulation of determinant oncogenes during 
leukaemogenesis (Dou, et al., 2010).  
miR-196a present in the plasma has also been indicated as an effective early 
marker for patients with pancreatic carcinoma (Liu, et al., 2012). 
Recently, many studies research the association between rs11614913 single-
nucleotide polymorphism (SNP) in hsa-miR-196a2* and cancer susceptibility, such as 
breast cancer, lung cancer, hepatocellular carcinoma, gastric cancer, esophageal cancer 
and glioma. This SNP has also been indicated as a prognostic biomarker for non-small 
cell lung cancer, if the mature miRNA* is considered, once there was not a change in 
the precursor levels of both forms (Hu, et al., 2008). These results were found to be true 
also for breast cancer. The SNP referred before affects the maturation of the pre-miRNA 
and affects target mRNA possibilities (increasing or decreasing the affinity), modulating 
cancer susceptibility. A CpG island was found upstream this gene which influences its 
expression. This SNP can have different effects depending on race (Hoffman, et al., 
2009; Christensen, et al., 2010; Chu, et al., 2011). However, a clear link between 
genetic variations and functional alternations remains to be established. 
Regarding miR-196a1, it is transcribed from the minus strand [4] and has a 9 
nucleotide seed region which is longer than most miRNAs. The expression of this 
miRNA is spatio-temporally regulated during development and pathologies (Tripurani, 
et al., 2011). 
Additionally, cell culture experiments supported high miR-196a1 levels could 
supress the activities of various cancer related genes, such as ANXA1 (annexin A1), 
suppression of which was well documented in various cancers (Tian, et al., 2010). 
Although miR-196a1 generally has a pro-oncogenic influence in human cancers 
in some studies on breast cancer and melanoma it seems to have an onco-supressor 
behavior (Schimanski, et al., 2009; Li, et al., 2010). 
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II. Scope of the thesis 
 
The aim of this project is to discover the potential link between deregulation of 
the PI3K/AKT pathway and deregulation of miR-196a expression in non-small cell lung 
cancer. Furthermore, it is intended to unravel the role of miR-196a in cellular processes 
related to tumour progression such as influence in replicative potential and migration in 
vitro and potential to induce tumour development in vivo. 
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III. Material and Methods 
 
With the bioinformatic tool Target Scan and the site microRNA.org three 
interesting targets were predicted for miR196a - FoxO1, FoxO3 and p27. These targets 
were chosen because they are involved in the PI3K/AKT pathway, and one of the aims 
of this work is to correlate miR-196a1 with this pathway in NSCLC. The first 
experiments done were to confirm these genes as true targets of miR-196a1. 
 The predicted target genes were amplified by PCR and cloned into pGL3 
control vector, represented in Figure 8. This vector contains a restriction site for XbaI 
endonuclease downstream of a gene that encodes luciferase (luc
+
), so this property is 
used to insert our 3’UTR in this place. If these are really target genes for the microRNA 
in study, is expected to see a downregulation of luciferase expression. After the 
insertion of the target gene in the pGL3 control vector, the vector name will be pGL3 
control-3’UTR target gene. 
 
 
Figure 8 - pGL3-Control Vector. Source: [7] 
 
III. 1. PCR to amplify the 3’UTR of target genes 
The 3’UTR of target genes were amplified by PCR with specifically designed 
primers, represented on table 1. The Taq polymerase utilized was from Euroclone and 
the instrument used was DNAEngine® Peltier Thermal Cycler (BioRad). 
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Primers Sequence 
Primer Forward FoxO1 CCCAATGTGTGCAGGTTATG 
Primer Reverse FoxO1 AGGTCCAAGGCTGTTCAATG 
Primer Forward FoxO3A GGCGGACTTTGTGTTTGTTT 
Primer Reverse FoxO3A CCATGCCAGGCTAATTTTGT 
Primer Forward p27 TTCATGGAATGGACATCCTGT 
Primer Reverse p27 CCTTCCCCAAAATTGCTTCT 
 
Table 1 -  Primers used to amplify the 3’ UTR of chosen target genes. 
 
The PCR products were analysed by agarose gel electrophoresis at 1% with 
incorporated ethidium bromide. The electrophoretic run occurred at 100 V, in an 
electrophoretic tank containing 1X TAE and the gel image was visualised with an UV 
transiluminator, using the QuantityOne 4.6.1 software. 
 
III. 2. Purification of 3’UTRs from PCR products  
 
After confirming that the 3’UTRs were amplified, the DNA had to be purified 
from the PCR products. The QIAquick PCR Purification Spin Protocol was preformed 
to this effect, as manufacturer’s recommendations. 
The DNA obtained was quantified in a NanoDrop spectrophotometer. 
 
III. 3. Nucleic Acid quantification 
Quantification of nucleic acids was made with a NanoDrop spectrophotometer 
ND-1000.  
First the equipment was initialized and calibrated using 2 µl of H2O milliQ. 
Then, the purity values (ratio between the absorbance at 260 nm and 280 nm and 
between the absorbance at 260 nm and 230 nm), and the concentration of nucleic acids 
was measured in ng/μl, depositing 2 µl of each sample in the instrument. 
 
III. 4. Quick Ligation Protocol 
First it was combined 50 ng of pGL3-Control vector with a 5-fold excess of 
insert, adjusting the volume to 10 µl with H2O milliQ. Then it was added 10 µl of 2X 
Quick Ligation Buffer and the solution was mixed. Subsequently it was added 1 µl of 
Quick T4 DNA Ligase followed by a thoroughly mix. The reaction was incubated at 
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room temperature for 15 minutes, after what it was chilled on ice and then used to 
transform bacteria. 
For each ligation protocol, there were made two different controls: α and β. The 
α control contains only the vector, the buffer and H2O to evaluate the efficiency of the 
vector’s digestion. On the other hand, the β control contains also the enzyme and 
therefore consents to evaluate the efficiency of the dephosphorilation of the vector. 
 
III. 5. Transformation Protocol 
Initially, the competent cells were thawed on ice for defrosting and it was 
transferred 5 µl of the ligation mixture in a 1.5 ml microcentrifuge tube. After 
defrosting, there were added 50 µl of competent cells to the DNA followed by a gentle 
mix by pipetting up and down. The mixture was incubated on ice for 30 minutes, 
pursued by a heat shock at 42ºC for 45 seconds. Meanwhile, it was prepared SOC 
medium (SOB and glucose [0,4%]). After the heat shock it was added 1 ml of room 
temperature SOC to each microcentrifuge tube, and the tubes were incubated at 37ºC for 
60 minutes at 1000 rpm in a thermomixer. 
Once the incubation was finished the microcentrifuge tubes were centrifuged at 
5000 rpm for 5 minutes, to pellet the bacteria. The supernatant of each tube was 
discarded leaving about 150 µl on which the cellules were resuspended. Following the 
resuspension, the cells were plated onto LB + ampicillin selection plates and placed in 
an greenhouse overnight at 37ºC. After this last incubation, the plates can be stored at 
+4ºC or the colonies formed can be analyzed right away by PCR. 
 
III. 6. PCR on colony 
The bacteria colonies were screened by PCR to verify the presence of the pGL3-
control vector containing the 3’UTR of the target genes. For that, the colonies were 
picked with a tip which was then mix in 20 µl of water. 3 µl of the bacteria solution 
were used to amplify by PCR and the remaining volume was conserved at +4ºC. 
The PCR primers are represented on table 2, considering that the primer reverse 
is equal to every samples once it is complementary to the vector. The Taq polymerase 
utilized was from Euroclone and the instrument used was DNAEngine® Peltier 
Thermal Cycler (BioRad). 
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Primers Sequence 
Primer Forward FoxO1 CCCAATGTGTGCAGGTTATG 
Primer Forward FoxO3 GGCGGACTTTGTGTTTGTTT 
Primer Forward p27 TTCATGGAATGGACATCCTGT 
Primer Reverse universal CGCGGAGGAGTTGTGTTTG 
 
Table 2 – Sequences of the primers used to amplify the insert from the bacteria. 
After the complete PCR program, the samples were run in an 1% agarose gel 
electrophoresis with ethidium bromide incorporated, so the band corresponding to the 
molecular weight of the 3’UTR of the gene of interest was seen. To discard the false 
positive results, the samples positive for PCR were subsequently analyzed through 
digestion with XbaI. 
 
III. 7. Miniprep 
To make the digestion with XbaI, plasmid DNA had to be amplified in bacteria. 
For the positive clones, the remaining volume of the suspension of bacteria in water, 
that was not used for PCR on colony, was grown in 3 ml of LB supplemented with 
ampicillin overnight at 37ºC at 250 rpm. Then, 2 ml of the liquid culture were 
centrifuged at 6000 rpm for 5 minutes in a microcentrifuge tube. 
Afterwards, the QIAprep Spin Miniprep kit by QIAGEN was used to extract 
plasmid DNA as manufacturer’s recommendations except for the elution volume used, 
which was 30 µl of H2O milliQ. Plasmid DNA was quantified using NanoDrop 
spectrophotometer. 
III. 8. Digestion with XbaI 
The plasmid DNA obtained from the Miniprep protocol was digested with XbaI 
enzyme, in order to rule out some false positive results from the PCR on colony 
protocol. The mix composition is showed on table 3. 
Reagents Volumes/ sample (µl) 
DNA 3 
Buffer 2 2 
10X BSA 2 
XbaI 0.5 
H20 milliQ 12.5 
  
Total Volume  20 
 
Table 3 – Mix used to preform the digestion of the plasmid with XbaI. 
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After mixing all the components, the solution was incubated at 37ºC for 1 hour 
without agitation in a Thermomixer comfort (Eppendorf). The samples were run in an 
1% agarose gel electrophoresis with ethidium bromide, using the non-digested vector 
pGL3-control as negative control.  
 
III. 9. Sample sequencing 
After observing which clones were also positive for digestion with the 
endonuclease XbaI, samples were prepared for sequencing at Primm. Samples for 
sequencing were concentrated 150 ng/µl in a total of 10 µl from purified plamid DNA. 
 
III. 10. Maxiprep 
After confirming which clones were positive for digestion and for sequencing a 
plasmid DNA extraction was made, this time using the QIAGEN® Plasmid Maxi Kit. 
The remaining 1ml of liquid culture that was not used to do the Miniprep was added to 
500 ml of LB supplemented with ampicilin, and the bacteria were allowed to grow at 
37ºC at 250 rpm overnight. QIAGEN protocol was followed as recommended. The 
DNA pellet was resuspended in 150 µl of H2O milliQ and the concentration was 
measured with a NanoDrop spetophotometer.  
 
III. 11. Cellular culture 
NCI-H460 were cultured in RPMI 1640 medium supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin (P/S) in petri plates treated for cell 
growth, as manufacturer’s recommendation.  
On the other hand, HEK-293T were cultured in DMEM supplemented with 10% 
fetal bovine serum (FBS) and 1% P/S. 
All cells were maintained in standard conditions in an incubator at 37ºC in 5% 
CO2 and splitted every two or three days, using trypsin. 
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NCI-H460 
H460 shAKT1 
H460 shAKT1 
miR 196a 
H460 shAKT1 
Empty Vector 
H460SCR 
H460 SCR 
anti-miR 196a 
H460 SCR 
Empty Vector 
a) b) 
III. 12. Cellular system 
In order to evaluate the effects of miR-196a1 in lung cancer and correlate it to 
the PI3K/AKT pathway simultaneously, a complex cellular system was chosen. The 
cellular system is perceptible in Figure 9, where each line represents a different 
infection, and each square a stable cell line. 
 
 
 
 
 
 
 
 
 
The lenti-vectors used to infect the cells were purchased in System Biosciences 
and are represented in Figure 10a and b. 
 
Figure 10 -- Lenti-vectors used to infect the cell lines. (a) This vector as it is represented in the figure, 
without any further insert is called troughout this work as “Empty Vector” and serves as a control vector. hsa-
miR-196a was inserted in the place represented by the red arrow, being under the control of constitutive CMV 
promoter. (b) Vector used to block hsa-miR-196a. 
 
III. 13. Dual-Luciferase® Reporter Assay (Promega) 
The first step was to transfect HEK-293T cells with the siPORT™ NeoFX™ 
transfection agent, following the protocol as manufacturer’s recomendations. Depending 
on the condition to be tested, the samples were prepared as represented in Table 4.  
 
 
Figure 9  - Cellular system used. 
III. Materials and Methods 
49 
 
 
 
Condition number Vector pGL3 
control 
pGL3 control-3’UTR 
target gene 
Renilla Small RNA 
1 - FoxO1 √ Negative control 
2 - FoxO1 √ miR-196a1 
3 - FoxO3 √ Negative control 
4 - FoxO3 √ miR-196a1 
5 - p27 √ Negative control 
6 - p27 √ miR-196a1 
7 √ - √ Negative control 
8 √ - √ miR-196a1 
9 - - √ Negative control 
10 - - √ miR-196a1 
 
Table 4 – In this table there are represented the ten conditions (including controls) used to perform 
the Dual-Luciferase® Reporter Assay.  
The luciferase assay was also done as suggested by the manufacturer.  
 
III. 14. Production of stable clones 
III. 14.1. Transfection of HEK-293T  
First the HEK-293T cells were grown to 60 to 80% confluence on the day prior 
to the infection to produce the virus. The following quantities are indicated for one 
construct of interest and for one petri dish of HEK-293T cells at the right confluence 
and this procedure is to be done under a class II laminar flux chamber. 
Afterwards, a mix is prepared containing 13 µg of the vector of interest, 12 µg of 
VSVG (envelope protein) and 18 µg of Δ8.9 (allows packaging). This mix is then added 
to CaCl2 (0.25 M) in a microcentrifuge tube. BES (®Sigma) was added to a conical tube 
of 50 ml by BD Falcon™, and the previous solution of CaCl2 and DNA is added to 
BES, drop by drop, while air is inflated to allow the reaction between them to occur. 
The reaction is incubated at room temperature for 30 minutes, allowing the crystals 
between the calcium of CaCl2 and the fosfate of BES to form and then, the solution is 
added drop by drop to the cellular culture, homogenizing at the end. 
The culture medium is changed after 16 hours, adding fresh medium, and after 8 
hours (24h from the transfection) the first lentiviruses are recovered and filtered. Fresh 
medium was added again to the HEK-293T plates and at 48h from the transfection, 
lentiviruses are recovered again. The lentiviruses that are not used to infect cells at the 
moment of the recover are stored at -80ºC. 
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The bivalent ions promote the entering of DNA trough the membrane of the 
cells. This mechanism is not clear but it is thought to be by endocitosis. 
III. 14. 2. Infection with lentiviruses 
On the day previous to the infection the cells to infect were plated on petri plates 
(1x10
5
 for NCI-H460) of 60mm with complete medium. The lentiviruses were produced 
by the protocol described formerly. 
When the lentiviruses were recovered at 24h from the transfection, the 
suspension was used to substitute the medium of the cells in which was mixed 1 µl of 
polybrene (8 mg/ml) for each ml of suspension added to the cell culture. This polymer 
is added because it helps the process of transduction by camouflaging the negative 
charges present in the cellular membrane, and therefore permeabilising it. The first 
cycle was done overnight. 
The morning after, the viral suspension was changed, starting a 10 hours 
incubation followed by another overnight incubation after changing the viral suspension 
again. The last viral incubation was a 10 hour one after which the viral suspension was 
recovered and fresh medium was added to the cells. 
After 36 hours the medium was changed to medium containing 1.5 µg/ml of 
puromincin, so our cells of interest were selected. 
 
III. 14. 3. Fluorescent Clone picking 
After one week in selection medium, the cells were splitted and plated at a very 
low confluence so that the cells were completely separated from each other. The cells 
were then allowed to grow and form clones. The clones were observed in an inverted 
microscope, with a fluorescent lamp, and the fluorescent ones were signed. Under a 
laminar flux chamber the clones were picked with a micropipette of 200 µl with 50 µl of 
trypsin. The tip was positioned vertically over the clone and it was permitted the contact 
by capillarity between the clone and the trypsin for about one minute. Afterwards, it 
was dispensed just a little of trypsin over the clone and it was aspired. The cells in the 
clones were separated by pipeting up and down in a well of 24-well plate, and were kept 
in medium with selection, during amplification. 
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III. 15. Total protein extraction 
To extract proteins from cells grown in adherent culture, the culture medium was 
removed and the cells were washed with 1X PBS, being detached mechanically from 
the plate with a scraper. The cells were recovered to a microcentrifuge tube of 2 ml and 
the plate was washed 1X PBS to remove any remaining cells. The cells were then 
pelleted in a refrigerated microcentrifuge at 4ºC for 5 minutes at 6000 rpm. 
All the steps of this protocol were done using ice and the solutions were also 
kept in ice. 
The ELB (Lysis Buffer) consists on an aqueous solution containing 50mM of 
Hepes (pH 7), 250mM of NaCl and 5% Nonidet-p40 (NP-40). 
In order to avoid protein degradation by proteases, protease inhibitors (10X 
Protease inhibitor SIGMAFAST
™
 Protease Inhibitor Tablets), phosphatases inhibitors (1 
mM of Na3Vo4, 1 mM of NaF, 1 mM of PMSF, 10 nM of Okadaic Acid) and a reducing 
agent (1 mM of DTT) must be added to ELB before lysing the cells. The final solution 
was prepared, just before using it, otherwise the inhibitors may become inactive. 
The pellet was resuspended in complete lysis buffer in a variable volume based 
on the size of the pellet. The cell suspension was incubated on ice for 30 minutes and 
then centrifuged in a refrigerated centrifuge at 4ºC for 30 minutes at 13000 rpm. The 
supernatant was recovered to a microcentrifuge tube of 1.5 ml and protein concentration 
was determined by a standard Bradford Assay (BioRad) in a Beckman DU 530 
spectrophotometer.  
 
III. 16. Western Blot 
This technique was used to analyse the protein expression in the different cell 
lines. 
Poliacrylamide gels were prepared at two different acrylamide concentrations, 
10 or 12.5%, according to the molecular weight of the proteins in study.  
After complete polymerization of the gel, it is transferred to a electrophoresis 
tank that was filled with a running buffer containing 25 mM of TRIS, 250 mM of 
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Glicine (pH 8.3) and 0.1% of SDS. 50 µg of protein for each cell line were dispensed in 
the wells, and the gels were run at 100 V. 
When the proteins were separated between them, the run was stopped and 
fractionated proteins were transferred from the gel to a nitrocellulose membrane (Protan 
Nitrocellulose Transfer Membrane, Schlicher & Schuell, Germany) in a 1X transfer 
buffer containing 25 mM of TRIS, 250 mM of Glicina and 20% of methanol, for 1.5 
hours at 100 V. 
After transferring, the membranes were colored with 1X Red Ponceau (ATX 
Ponceau S Red staining solution, FLUKA) for 1 minute at room temperature in order to 
validate the transferring homogeneity and quality. Next, the membranes were washed, 
first in H2O bidistillated, then in TTBS (1X TBS and 0,1% Tween) and were pre-
hybridized for 1 hour in a solution of TTBS containing also 5% Nonfat dried milk 
powder (AppliChem) and 3% BSA in order to block the non-specific hybridization sites 
of the primary antibody. Subsequently 3 washes of 5 minutes each were made before 
incubating with the primary antibodies diluted in 1X TBS, 3% BSA, 0.02% NaAzide 
and 100 mg of Phenol Red, overnight at 4ºC, with agitation. 
The next day, the primary antibody was recovered and the membranes were 
washed for 5 minutes, 3 times with TTBS. After that, the membranes were incubated 
with the respective secondary antibody (rabbit or mouse), diluted at 1:2500 in a solution 
of TTBS with 5% of nonfat dried milk powder, for 1 hour, followed by 3 washes of 5 
minutes each with TTBS.  
Next the membranes were incubated for 1 minute with an amplified 
chemiluminescence kit, ECL (Amersham Inc.), which allows the operator to see the 
chemiluminescence on High performance chemiluminescence film (Amersham Inc.) 
due to the reaction between the substrate present on ECL and the peroxidase covalently 
bound to the secondary antibody. The primary antibodies used in this thesis were the 
following: Anti-FoxO3 (rabbit), diluted 1:400 (Cell Signaling TECHNOLOGY
®
, 
#2497); Anti-FoxO1 antibody (rabbit), diluted 1:500 (Cell Signaling TECHNOLOGY
®
, 
#2880); Anti-p27 antibody (mouse), diluted 1:500 (Santa Cruz Biotechnology, sc-
1641); Anti-α-Tubulin (mouse) concentrated 0.25 µg/ml (NeoMarkers, #MS-581). 
 
III. Materials and Methods 
53 
 
III. 17. RNA extraction 
To extract RNA from cells grown in adherent culture, a similar procedure to that 
for proteins was performed to remove cells from the petri plates. For total RNA 
isolation, TRIzol Reagent (Invitrogen) protocol was followed as company’s 
suggestions. The RNA concentration was determined using the NanoDrop 
spectrophotometer, as described before. 
 
III. 18. cDNA production  
cDNA from miR-196a1 and genes chosen was obtained following QIAGEN 
protocol, using miScript Reverse transcription procedure. 1 µg of RNA was used, and 
the concentration of cDNA obtained was measured in a NanoDrop spectrophotometer.  
III. 19. Real-Time PCR quantification 
miR-196a1 expression levels were evaluated by Real-Time quantitative PCR. 
The miScript Real-Time PCR for detection of miRNA or Noncoding RNA procedure by 
QIAGEN was performed using 20 ng of cDNA. RNU6B was used to normalize the Ct 
values. 
To confirm the target genes of miR196a, the quantitative expression of those 
genes was also analyzed by Real-Time PCR using 1X Sybr Green PCR Master mix 
(Applied Biosystems) and a total of 20 ng of cDNA. HPRT was the housekeeping gene 
chosen to compare Ct values and the primers, by Primm srl, used are represented in 
table 5. 
 
 
 
 
 
 
 
 
The experiment was conducted in Applied Biosystem 7900HT Fast Real-Time 
PCR System, using the program defined for Fast SYBR Green Master Mix (Applied 
Biosystems) and analyzed with SDS Enterprise Database software. 
Primers Sequence 
Primer Forward FoxO1 AAGGGTGACAGCAACAGCTC 
Primer Reverse FoxO1 TTCTGCACACGAATGAACTTG 
Primer Forward FoxO3A CTTCAAGGATAAGGGCGACA 
Primer Reverse FoxO3A CGACTATGCAGTGACAGGTTG 
Primer Forward p27 TTTGACTTGCATGAAGAGAAGC 
Primer Reverse p27 AGCTGTCTCTGAAAGGGACATT 
Primer Forward HPRT GGCCAGACTTTGTTGGATTTG 
Primer Reverse HPRT TGCGCTCATCTTAGGCTTTGT 
Table 5 – Primers used for Real-Time PCR 
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III. 20. Biological Assays 
III. 20. 1. MTT Proliferation Assay 
2000 cells were plated for each well on a 96-well plate in RPMI-1640 
complemented with 1% FBS. The experiment lasted for 4 consecutive days, so 4 
different plates were made and 1 was used on each day. On the measuring day, 10 µl of 
MTT (5 mg/ml) were added to each well. The MTT was allowed to incubate with the 
cells for 2 hours inside the cell incubator and after that it was removed and 100 µl of 
isopropanol were placed on each well. The plate was then incubated at room 
temperature with agitation for 10 minutes after what a violet precipitated was observed. 
The absorbance at 570 nm was read in EnVision™ 2103 Multilabel Reader (Perkin 
Elmer). 
 
III. 20. 2. Migration Assays 
III. 20. 2. 1. Wound Healing Assay 
Cells were grown in a 6-wells plates and when they reached 100% confluence 
there were made 3 scratches with a tip of 10 µl in each well, for each scratch there were 
chosen and signed 3 fields to photograph and follow the migration of the cells for 48h. 
Photos were taken at 0h, 12h, 24h, 36h and 48h. Once the scratches were made, the cells 
were maintained in RPMI 1640 complemented with 0.5% of BSA, so that the effect 
observed was mainly due to cellular migration and not to proliferation. Before each 
photo was taken, it was made a wash with PBS and a culture medium substitution. 
 
III. 20. 2. 2. Transwell Migration Assay 
In a Multiwell of 24 wells was added to half of the wells 700 µl of complete 
culture medium, then the modified Boyden chambers were placed in those wells. 
The cells of each line were counted with the Trypan Blue method, using a 
Bürker chamber. 1x10
5
 cells were resuspended in 100 µl of RPMI-1640 without any 
supplements and added to each modified Boyden chamber. For each cell line a duplicate 
was made. 
After 24h the cells were fixed and colored. First, the modified Boyden chambers 
were translocated to another well, and the medium was removed with a micropipette. A 
wash with PBS was carefully made and the excess of cells that have not migrated was 
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removed with the help of a cotton swab from the upper part of the chamber. The PBS 
was then discarded. 
It was added to each modified Boyden chamber (in the upper and in the lower 
part) 1 ml of cold methanol. The multiwell was put at -20ºC for 20 minutes after what 
the methanol was removed following the same method as for the removal of the 
medium and PBS. 
To color the cells, 1 ml of 0,01% Crystal Violet in 20% ethanol was added as it 
was done with the methanol, incubating at room temperature for 15 minutes. The excess 
of Crystal Violet that remained in the upper part of the modified Boyden chamber was 
removed with the help of a cotton swab, so a clearer view of the cells was possible.  
Several fields were photographed for each Boyden chamber and the cells for 
each field were counted. 
 
III. 20. 3. Xenograft Formation Assay 
Cells (2.5x10
6
) were resuspended in 50 µl of PBS and 50 µl of Matrigel growth 
factor reduced (BD Biosciences), so that the volume injected in each mouse was 100 µl 
on each side. Cells were then subcutaneously inoculated in nude mice of 6 weeks old. 
A biologic triplicate was made for each condition, and all injections followed the 
scheme represented in Figure 11. 
 
Figure 11 - Schematic illustration showing how cells were inoculated in mice. Source: [8]    
 
III. 21. Statistical analysis 
All data were statistically analyzed with the program GraphPad Prism 5, with the 
most correct approach – one-way or two-way ANOVA - being chosen for each 
experiment. The post-test used was the Bonferroni post-test. 
Cells expressing vector of interest 
Cells expressing control vector  
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IV.1. Previous Results  
 
Previously to the start of this thesis project there were made some experiments 
that allowed further developments. NCI-H460, a non-small cell lung cancer cell line 
was genetically modified for the knockdown of the PI3K/AKT pathway through the 
silencing of AKT1, AKT2 and PI3K. By microarray hybridization several differentially 
expressed miRNAs were identified in lentiviruses-infected cells compared to the control 
cell lines (from this point on called Scramble or SCR). Among them 9 miRNAs (hsa-
miR-146a, hsa-miR-584, hsa-miR-876-3p, hsa-miR-218, hsa-miR-551b, hsa-miR-33a, 
hsa-miR-29c, hsa-miR-203, hsa-miR-196a) were chosen based on the highest fold 
change values. These results were validated by Real-Time PCR. 
The expression of these 9 miRNAs was also analyzed in 29 human primary lung 
cancer samples (mostly adenocarcinomas) by Real-Time PCR. The results obtained are 
represented in Graphic 1. 
 
Graphic 1 - miRNA expression fold change in tumor samples when compared to normal tissue 
samples. 
In Graphic 1 is evident the over-expression of hsa-miR196a in tumor samples 
when compared to normal tissue samples, being the miRNA with the major fold change 
in all samples. Fold changes in miRNA expression throughout this work will be 
considered significant when the values are higher than 2 or lower than 0.6. 
Furthermore, a Real time PCR was performed in different cancer cell lines and 
compared to a normal immortalized Human bronchial epithelial cells – NHBE – to see 
if the expression of hsa-miR-196a was modulated. The cancer cell lines are derived 
from different tumor types. BEN derived from squamous lung carcinoma, NCI-H23, 
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NCI-H522 from adenocarcinoma, NCI-H460 from large cell carcinoma, NCI- H292 
from mucoepidermoid carcinoma, H28 from mesothelioma and H596 from 
adenosquamous carcinoma. In Graphic 2 is evident that in all cancer cell lines, miR-
196a1 expression is up-regulated. Moreover, it can be observed that in adenocarcinoma 
cell lines this up-regulation is very emphasized followed by the cell line representing 
large cell carcinoma and the cell adenosquamous carcinoma. Thereby it seems that 
although miR-196a1 is over-expressed in all lung cancer cell lines, this is more evident 
in all cell lines representing NSCLC. 
 
Graphic 2 – hsa-miR-196a1 fold change in lung cancer cell lines compared to a 
immortalized cell line (NHBE). 
 
In Graphic 3 are present the results for the differential expression of hsa-miR-
196a1 for NCI-H460 cell lines compared to the control cell line. This cellular system 
revealed a down-regulation of hsa-miR-196a1 in interfered cells respect to their control. 
As cells interfered for AKT1 were the ones showing a major down-regulation of hsa-
miR-196a1, these cells were chosen to study the impact of miR-196a1 over-expression 
and to observe if this over-expression could restore the effect of AKT1 presence in 
cells. 
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Graphic 3 - hsa-miR-196a1 expression in NCI-H460 derived cell lines. 
IV.2. Results  
 
IV.2.1. Choice and Confirmation of miR-196a1 targets correlated 
to PI3K/AKT pathway. 
IV.2.1.1. Choice of hsa-miR-196a1 targets 
In order to choose hsa-miR-196a1 targets that are correlated to the PI3K/AKT 
pathway, two data bases were consulted TargetScan.org and microRNA.org. The 
predicted targets were matched to the mRNA expression profiling of NCI-H460 
modified system obtained by a Microarray analysis. FoxO1, FoxO3 and CDKN1B (p27) 
were chosen for further studies. 
 
IV.2.1.2. 3’UTR amplification 
3’UTR of the genes of interest were amplified as described before. The 
amplification of 3’UTR of p27’s gene is represented on Figure 13. In Figure 12 the 
amplification of 3’UTRs of FoxO1 in the first lane and FoxO3 in the second lane are 
presented.  
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  Figure 13 - Agarose 
gel showing the 
amplification of 
3’UTR of p27. 
 
Figure 12 - Agarose 
gel showing the 
amplification of 
3’UTRs of FoxO1 in 
the first lane and 
FoxO3 in the 
second lane. 
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IV.2.1.3. Colonies screening by PCR 
After the amplification of the 3’UTR of the genes of interest, these inserts were 
cloned into pGL3-control vector. Bacteria were transformed to amplify this construct. 
The colonies which were successfully transformed with the pGL3-control vector 
containing the 3’UTRs are named positive clones. In order to identify the positive 
clones, the protocol of PCR on colony was performed and the PCR products were run in 
an agarose gel. 
In Figures 14, 15 and 16 are presented the agarose gels which allowed the 
identification of the true positive clones used in further procedures. The lanes which do 
not show any visible band represent negative clones, thus, colonies that have not 
integrated the pGL3-control vector with the insert. 
     
 
 
 
IV.2.1.4. Digestion with XbaI 
The samples positive for PCR were subsequently analyzed through digestion 
with endonuclease XbaI, which restriction site is present in pGL3-control vector, to rule 
out the false positives. 
To make the digestion with XbaI, plasmid DNA was extracted from the bacteria 
following the Miniprep protocol. Figures 17, 18 and 19 show the digestion of plasmid 
DNA of positive clones for PCR. 
 
   
 
 
 
 Figure 15 - Screening of 
colonies positive for FoxO1 
3’UTR. 
Figure 14 - Screening of colonies 
positive for p27 3’UTR. 
 
Figure 16 - Screening of 
colonies positive for FoxO3 
3’UTR. 
Figure 17 - Digestion of 
positive clones for (for PCR) 
p27 with XbaI. 
 
 
Figure 19 - Digestion of 
positive clones (for 
PCR) for FoxO1 with 
XbaI. 
Figure 18 - Digestion of positive 
clones (for PCR) for FoxO3 with 
XbaI. 
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IV.2.1.5. Sequencing results 
In order to be sure that the clones were truly positive, the samples positive for 
digestion with XbaI were sequenced. The results of sequencing were analyzed with the 
FinchTV software, so as to confirm that the amplified sequence is the sequence of the 
3’UTR expected and to confirm the presence of the miRNA Responsive Element 
(MRE) for hsa-miR-196a1. In Figures 20, 21 and 22 are presented the images extracted 
from FinchTV software, highlighting the MRE for hsa-miR-196a1. These constructs 
will be used further on to perform the Dual Luciferase Report Assay to validate the 
binding of hsa-miR-196a to the 3’UTRs of the target genes. 
 
 
Figure 20 - Sequencing results for the positive clone for FoxO1 used in further experiments. The 
highlighted region represents the sequence recognized by hsa-miR-196a1. 
 
Figure 21 - Sequencing results for the positive clone for FoxO3 used in further experiments. The 
highlighted region represents the sequence recognized by hsa-miR-196a1. 
 
Figure 22 - Sequencing results for the positive clone for p27 used in further experiments. The 
highlighted region represents the sequence recognized by hsa-miR-196a1. 
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IV.2. Production of stable clones  
 
Previously to this microRNA approach, the PI3K-AKT pathway in lung cancer 
was already being molecularly dissected by co-workers, so the cell lines to see the 
specific effect of some alterations to this pathway had already been obtained. Previous 
data led to the choosing of cell lines to be further infected. The main goal was now to 
produce stable clones where an inversion of the expression pattern of hsa-miR-196a was 
observed, by infecting the cell line where it was over-expressed with an anti-miR-196a 
vector, the line that had a knockdown expression with a hsa-miR-196a vector, and both 
lines with the equivalent Empty Vector. As the vectors used to infect the cells contain 
the gene which encodes GFP, the expression of this protein allowed the picking of 
fluorescent clones and further amplification. Figures 23 to 26 show the cell lines used to 
make further experiments. It is clear that the nearly 90% of these cells express the 
vector of interest, which gives reliability to the results presented using these cell lines as 
a start point.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 - NCI-H460 shAKT1 infected with the Empty Vector ( H460 shAKT1 EV). 
At the left a photo of a field without fluorescence light and at the right a photo of the 
same field taken with fluorescence light. 
Figure 24 - NCI-H460 shAKT1 infected with the hsa-miR-196a1 Vector (NCI-H460 
shAKT1 miR-196a1). At the left a photo of a field without fluorescence light and at the 
right a photo of the same field taken with fluorescence light. 
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IV.2.1. Confirmation of the alteration of hsa-miR-196a1 expression in the 
cellular system. 
In order to confirm the over-expression or down-regulation of hsa-miR-196a1, a 
Real-time PCR was performed. In Graphic 4, is visible the over-expression of hsa-miR-
196a1 in NCI-H460 shAKT1 cells infected with the lenti-vector containing the miRNA 
when compared with the same cells infected with the empty vector. 
Figure 25 - NCI-H460 SCR infected with the Empty Vector (H460 SCR EV). At 
the left a photo of a field without fluorescence light and at the right a photo of the 
same field taken with fluorescence light. 
Figure 26 - NCI-H460 SCR infected with the anti-miR-196a Vector (H460 SCR 
anti-miR-196a). At the left a photo of a field without fluorescence light and at the 
right a photo of the same field taken with fluorescence light. 
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Graphic 4 - Over-expression of hsa-miR-196a1 in NCI-H460 shAKT1 infected with the vector 
containing the miRNA when compared to NCI-H460 shAKT1 infected with the Empty Vector.  
 
hsa-miR-196a1 knockdown in NCI-H460 SCR cell line infected with the anti-
miR-196a lenti-vector compared to the same cell line infected with the empty vector is 
visible in Graphic 5. 
 
Graphic 5 - hsa-miR-196a1 knockdown in NCI-H460 SCR infected with the vector containing the 
anti-miRNA when compared to NCI-H460 SCR infected with the Empty Vector.  
 
Observing the last two graphics, one can conclude that there is a different 
modulation of hsa-miR-196a1 in the cell lines infected. Therefore, these cell lines 
constitute a good model to study the biological effect of this miRNA and to correlate it 
to the PI3K/AKT pathway. 
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IV. 3. Confirmation of target modulation 
IV.3.1. Luciferase Assay 
The plasmid DNA from positive clones for sequencing was amplified and used 
to transfect HEK-293T cells with the siPORT™ NeoFX™ transfection agent. The 
values for luciferase activity were obtained following the Dual-Luciferase® Reporter 
Assay (Promega).  
In Graphic 6 we can see that cells that were both transfected with pGL3-control 
containing the insert of FoxO1 3’UTR and hsa-miR-196a show a knockdown of 
luciferase activity respect to the same cells transfected with negative control (SCR) and 
the vector of interest. This happened because when the miRNA binds to the 3’UTR of 
its target gene the mRNA becomes instable and as the luciferase gene is no longer 
expressed, is visible a down-regulation of the luciferase activity, whose gene is directly 
linked to the insert. Thereby, when a down-regulation of luciferase activity is evident 
one can infer that the insert is a target of the miRNA in study.  
However, the results for FoxO3, represented on Graphic 7, do not show this 
reduction indicating that this is not a relevant target for hsa-miR-196a. On the other 
hand, cells transfected with the vector containing p27 3’UTR show a strong reduction of 
luciferase activity showing that this is a target for hsa-miR-196a1 as can be seen in 
Graphic 8. 
 
Graphic 6 – Down-regulation of luciferase activity on cells transfected with pGL3-control containing 
the insert of FoxO1 3’UTR and hsa-miR-196a. 
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Graphic 7 - Cells transfected with pGL3-control containing the insert of FoxO3 3’UTR and hsa-miR-
196a do not show a significant reduction of luciferase activity.  
 
Graphic 8 – Strong down-regulation of luciferase activity on cells that were both transfected with 
pGL3-control containing the insert of p27 3’UTR and hsa-miR-196a. 
 
IV.3.2. Real-time PCR Analysis 
Real-time PCR was carried out in order to evaluate if there is a differential 
regulation of mRNAs of the genes of interest in the cellular system created. On Graphic 
9a, b, is visible that the increase or knockdown of miR-196a1 does not have a 
significant effect on FoxO1 mRNA levels, considering the threshold values 0.5 and 2, 
indicating that the miR-196a1 does not promote the degradation of this mRNAs. 
(a)        (b) 
 
Graphic 9 – The graphics represent the modulation of FoxO1 mRNA in the cell lines created. (a) 
Modulation of FoxO1 mRNA in cells expressing the miR-196a1 vector is not significant compared to its 
control. (b) Modulation of FoxO1 mRNA in cells expressing the anti-miR-196a1 vector is not considered 
significant compared to its control. 
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Fold changes in p27 mRNA and FoxO3 mRNA showed identical results to those 
obtained for FoxO1 (Graphics 10a, b and 11a, b). In conclusion, miR-196a1 does not 
seem to modulate the levels of mRNA of any of the genes in study, indicating that its 
seed sequence is not fully complementary to any of the 3’UTR of the genes in study. 
    (a)      (b) 
Graphic 10 - The graphics above show the modulation of p27 mRNA in the cell lines created. (a) 
Modulation of p27 mRNA in cells expressing the miR-196a1 vector is comparable to its control (b) Modulation 
of p27 mRNA in cells expressing the anti-miR-196a1 vector is not considered significant compared to its 
control. 
(a)          (b) 
Graphic 11 - The graphics represented above show the modulation of FoxO3 mRNA in the cell lines 
created. (a) The difference in fold change of FoxO3 mRNA in cells expressing the miR-196a1 vector is not 
significant when compared to its control. (b) Modulation of FoxO3 mRNA in cells expressing the anti-miR-
196a1 vector is not considered significant compared to its control. 
           
IV.3.3. Western Blot Analysis 
miRNAs can also down-regulate the translation of mRNAs with which they do 
not have a fully complementarity. The levels of protein expression of the genes in study 
were thereby analyzed through Western Blot analysis and the signals were normalized 
with an antibody against tubulin, a protein which has a constitutive expression. In figure 
28 is visible a knock-down of the expression of FoxO1 on the cell line expressing the 
miR-196a1 vector when compared to its control (H460 shAKT1 EV) and a up-
regulation on the cell line expressing the anti-miR-196a1 vector when compared to the 
control cell line (H460 SCR EV). The results obtained for p27 are the similar to those 
obtained for FoxO1 and are shown in figure 27.  
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These results indicate that miR-196a1 regulates the expression of these genes at 
protein synthesis level, inhibiting it. The mechanism of this regulation is not known, but 
it falls under the scope of this project. 
 
 
 
 
 
      
 
 
 
 
 
 
 
In figure 29, is visible that the protein levels of FoxO3 are low in general and a 
regulation of FoxO3 by miR-196a1 is not observed once the bands for H460 shAKT1 
miR-196a and its control appears to have no difference between them. These 
observations may lead to the conclusion that FoxO3 is not a true target of miR-196a1. 
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Figure 27  - Western Blot using an anti-p27 
antibody shows a modulation of p27 expression by 
miR-196a1. The signals are normalized with an 
anti-Tubulin antibody. 
Figure 28 - Western Blot using an anti-FoxO1 
antibody reveals a modulation of FoxO1 
expression by miR-196a1. The signals are 
normalized with an anti-Tubulin antibody. 
Figure 29 - Western Blot using an anti-
FoxO3 antibody does not show a modulation 
of FoxO3 expression by miR-196a1. The 
signals are normalized with an anti-Tubulin 
antibody. 
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IV.4. Biological Assays 
IV.4.1. MTT Results 
This assay was performed for all cell lines, produced in this work and parental 
cells, simultaneously. The number of cells was inferred from the absorbance read in 
EnVision™ 2103 Multilabel Reader, considering that the value 0.1 corresponded to 
1000 cells.  
Graphic 12 corresponds to H460 shAKT1 miR-196a1 and the respective 
controls. It is clear that the cell line H460 shAKT1 miR-196a1 has a proliferative 
advantage when compared to its direct controls, H460 shAKT1 and H460 shAKT1 EV, 
being the cell line that comes the closest to its indirect control H460 SCR. Statistical 
analysis using two-way ANOVA and the Bonferroni post-test, indicated that H460 
shAKT1 miR-196a1 is statically different from H460 shAKT1 and H460 shAKT1 EV, 
from 72h of the beginning of the assay, presenting a p-value of p<0.0001. No statistical 
significance was found in the difference between H460 shAKT1 and H460 shAKT1 
EV.  
 
Graphic 12 – Growing curve of H460 shAKT1 miR-196a1 presenting direct and indirect controls for 
this cell line. 
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Graphic 13, in its turn, represents H460 SCR anti-miR-196a1 and the respective 
controls. The cell line H460 SCR anti-miR-196a1 shows a reduced proliferative 
potential when compared to its direct controls, H460 SCR and H460 SCR EV, being 
also very close to its indirect control H460 shAKT1. Statistical analysis using 2 way 
ANOVA and the Bonferroni post-test, indicated that H460 SCR anti-miR-196a1 is 
statistically different from H460 SCR and H460 SCR EV, from 48h of the beginning of 
the assay, presenting a p-value of p<0.0001. No statistical significance was found in the 
difference between H460 SCR and H460 SCR EV.  
 
Graphic 13 - Growing curve of H460 SCR anti-miR-196a1 presenting direct and indirect controls for 
this cell line. 
 
IV.4.2. Wound healing assay 
Although photos have been made each 12 hours from the moment the scratches 
were made, the differences are more evident after 24 and 48 hours, so the analysis was 
made referring to this two time points. In figure 30 is visible the difference between the 
migration potential of H460 shAKT1 miR-196a1 and H460 shAKT1 EV, once after 48h 
the cells on the cell line H460 shAKT1 miR-196a1 have already migrated to fill almost 
half of the initial scratch. The same is not true for H460 shAKT1 EV that shows a 
reduced migratory capacity when compared to H460 shAKT1 miR-196a1. 
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Figure 30 - Images of the same fields were taken at 24h and 48h from the moment the scratch was 
made. On the first row is presented the difference obtained for the cell line H460 shAKT1 miR-196a1 and the 
migration of the cells is clear.  
 
In figure 31 it can be observed that the cell line H460 SCR anti-miR-196a1 has a 
minor migration potential than that of H460 SCR EV. After 24h is already evident that 
cells of the cell line H460 SCR EV have a strong migratory capacity comparing to H460 
SCR anti-miR-196a1. This difference is further accentuated at 48h.  
 
Figure 31 - Images of the same fields were taken at 24h and 48h from the moment the scratch was 
made. On the first row is presented the difference obtained for the cell line H460 SCR anti-miR-196a1. On the 
second row is visible that the cell line H460 SCR EV. 
Three measures of the scratch were made for each field at different time points 
(approximately in the same places) and these measures were then compared to each 
other to infer the percentage of reduction of the scratch.  
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In Graphic 14 are presented the percentage of reduction obtained for each cell 
line. Interestingly, at 48 hours the cell line H460 SCR anti-miR-196a1 and H460 
shAKT1 EV show approximately the same migratory capacity and the same happens for 
the cell lines H460 shAKT1 miR-196a1 and H460 SCR EV. This indicates that 
somehow the over-expression or knock-down of miR-196a1 is capable of inverting the 
phenotypes of the cells interfered for AKT1 or normally expressing AKT1 respectively, 
leading to the possibility that this miRNA modulates migration through the regulation 
of genes controlled by the PI3K/AKT pathway. 
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Graphic 14 – Percentage of reduction of scratches in the cell lines created. The patterns of migration 
obtained for the control cell lines are reversed by the over-expression or knock-down of miR-196a1. 
Statistical analysis performed using two-way ANOVA and a Bonferroni post-
test indicates that there is no statistical difference between H460 shAKT1 miR-196a1 
and H460 SCR EV and between H460 SCR anti-miR196a1 and H460 shAKT1 EV. On 
the other hand, the cell lines H460 shAKT1 miR-196a1 and H460 SCR anti-miR-196a1 
show a significant statistical difference from their direct controls, H460 shAKT1 EV 
and H460 SCR EV respectively, with a p-value of p<0.01. 
 
IV.4.3. Tranwell Migration Assay 
In order to confirm the results obtained for the wound healing assay and to 
understand if it the results were not influenced by the technique, another migration 
assay was preformed. The migration through the modified Boyden chamber forces the 
cells to pass through the pores of the membrane (physic barrier), as in the wound 
healing assay they did not have to surpass any physic obstacle to migrate. Nevertheless, 
the results obtained confirm a modulation of migration by miR-196a1.  
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Cells that have migrated are colored with a light violet shade. Figure 32 reveals 
that the cell line H460 shAKT1 miR-196a1 migrates more than H460 shAKT1 EV and 
that H460 SCR anti-miR-196a1 migrates less than its control H460 SCR EV. The 
pictures were taken with an inverted microscope with an amplification of 10X. 
 
Figure 32 - In this figure are represented the images of the bottom part of the modified Boyden 
chambers.  
Cells were counted in 8 fields randomly chosen, with an inverted microscope 
with an amplification of 20X. In graphic 15 are represented the average number of cells 
counted in each field for each cell line. Is evident that H460 shAKT1 miR-196a1 has a 
major number of migrating cells respect to all the other cell lines whereas H460 SCR 
anti-miR-196a1 shows a reduced number of migrating cells comparing to all the other 
cell lines.  
Statistical analysis was preformed doing a one-way ANOVA with a Bonferroni 
post-test. The results indicate that H460 shAKT1 miR-196a1 has a significant statistical 
difference from its control with a p-value of p<0.0001 and H460 SCR anti-miR-196a1 
also differs from H460 SCR EV, with the same p-value. 
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Graphic 15 – Average number of cells counted in each field for each cell line. 
 
IV.4.5. Xenograft 
Xenograft assay was preformed to evaluate the capacity of the cell lines created 
to induce tumorigenesis in vivo. After 3 weeks the cell line H460 SCR anti-miR-196a1 
was not able to induce tumorigenesis whereas its control, H460 SCR EV, had already 
induced the formation of tumors bigger enough to force the ending of the experiment 
and the consequent sacrifice of the nude mice (Figure 33). 
 
 
 
Figure 33 - Xenograft assay of the cell line H460 SCR EV (injected on the left side) and H460 SCR 
anti-miR-196a1 (injected on the right side). 
The results for the cell lines H460 shAKT1 miR-196a1 and H460 shAKT1 EV 
were not reproducible for the biological triplicate. After 5 weeks of the beginning of the 
experiment one nude mouse had to be sacrificed. This mouse had developed tumors 
induced by both cell lines, but the tumor induced by the cell line H460 shAKT1 miR-
196a1 was slightly bigger than the one induced by H460 shAKT1 EV (Figure 34a).  
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After another two weeks the other two nude mice were sacrificed. These two mice 
showed the development of tumors induced only for the cell line H460 shAKT1 miR-
196a1 whereas H460 shAKT1 EV was not able to successfully induce tumorigenesis 
(Figure 34b).  The results obtained showed that the cell line H460 shAKT1 miR-196a1 
seems to be more tumorigenic than H460 shAKT1 EV.  
 
 
 
 
 
 
 
 
(a)                                        (b)  
 
 
 
 
 
 
 
 
 
 
H460 shAKT1 
miR-196a1 
H460 shAKT1 
EV 
Figure 34 - Xenograft assay for cell lines H460 shAKT1 miR-196a1 and H460 shAKT1 
EV. (a) Nude mouse sacrificed 5 weeks after the beginning of the experiment. (b) Nude mice 
sacrificed 7 weeks after the beginning of the experiment. 
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V. Discussion 
 
Since its discovery, miRNAs have been associated with the regulation of every 
cellular process investigated so far and the alteration of its expression is linked to 
several human diseases.  
In cancer, they can act as oncogenes or tumour suppressor genes and may 
contribute to the loss of cell cycle control and increased proliferative capacity, 
characteristics of transformed cells. They can also contribute to the less differentiated 
state of tumours and can act simultaneously as apoptosis and checkpoint regulators 
directly or indirectly, regulating different targets. 
The modification of expression of several miRNAs and miRNA processing 
machinery have shown to regulate autocrine/paracrine loops, anti-apoptotic genes, 
genes that promote tumour vasculature development, cell cycle related genes, metastasis 
related genes and chemoresistance genes in lung tissue, contributing greatly to the 
initiation and progression of lung cancer. Their deregulation in NSCLC can be used to 
sub-classify NSCLCs but specific miRNA profiles may also predict prognosis and 
disease recurrence in early-stage NSCLCs. 
The role of hsa-miR-196a1 in oncogenesis seems to be cancer type-specific; 
nevertheless the over-expression of this miRNA is often associated with promotion of 
oncogenesis rather than its inhibition.  
Several miRNAs have been found to normally down-regulate the PI3K/AKT 
pathway activation, such as miR-205, miR-331, miR-125, miR-7 and miR-126, and 
their knockdown is associated with the activation of the pathway and tumour 
progression. However, over-expression of other miRNAs, such as miR-21, miR-214 and 
the cluster miR-17-92 is highly associated with the activation of this pathway 
(Santarpia, et al., 2010). Schimanski et al., have validated an increase of 
phosphorylation of AKT in cells over-expressing hsa-miR-196a. Although this 
approach is interesting, the cellular system used in the presented work does not allow 
this kind of analysis once some of the parental cells are interfered for AKT1, thereby the 
levels of phosphorylation of AKT could not be accessed. 
The target genes chosen to this study are regulated by the activation of 
PI3K/AKT pathway. FoxOs are one of the major targets of the PI3K/AKT signalling in 
the presence of growth factors and nutrients. Activation of the PI3K pathway promotes 
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phosphorylation, and consequent nuclear exclusion of the FoxOs resulting in the 
blockage of their growth inhibitory transcriptional functions. Since growth inhibitory 
functions of FoxOs involve activation of several proteins that include inhibitors of cell 
cycle such as p27, retinoblastoma protein, inducers of extrinsic as well as intrinsic 
apoptosis, and interactions with tumour suppressors such as p53. FoxOs are known to 
function in a tissue and context-dependent manner, and functional redundancy exists 
among them. FoxO proteins have as their transcriptional target PTEN, so their 
expression promotes the inhibition of PI3K/AKT pathway (Tzivion, et al., 2011; Zhang, 
et al., 2011).  
p27 may be directly or indirectly regulated by active AKT. AKT is capable of 
directly phosphorylating p27, causing its cytoplasmic retention and subsequent 
degradation through the ubiquitin-proteasome pathway and can inhibit its transcription 
through FoxO phosphorylation and exclusion from the nucleus (Fujita, et al., 2002; 
Motti, et al., 2005; Rassidakis, et al., 2005). 
Target genes were experimentally confirmed by Dual Luciferase reporter assay. 
The pGL3-Control Vector was chosen because it provides a basis for the quantitative 
analysis of factors that potentially regulate mammalian gene expression by cis- or trans-
acting factors. The coding region for firefly (Photinus pyralis) luciferase has been 
optimized for monitoring transcriptional activity in transfected eukaryotic cells. The 
assay of this genetic reporter is rapid, sensitive and quantitative and XbaI site just 
downstream of luc
+
 gene facilitates insertions of the 3´ untranslated region of mRNAs. 
The presence of SV40 large T antigen in HEK-293T promotes replication from 
the SV40 origin found in the promoter of pGL3-Control Vectors. The combination of 
the large T antigen and the SV40 origin will result in a higher copy number of these 
vectors, which in turn may result in increased expression of the reporter gene compared 
to other cell and vector combinations [9]. There are several works in which this system 
has proven to be useful and has given good results (Visone, et al., 2007; Kulkami, et al., 
2011). 
This method allowed to confirm FoxO1 and p27 as targets of miR-196a1, but 
not FoxO3, once there was no significant reduction of luciferase activity when this 
3’UTR was inserted downstream of luc+ gene. Nevertheless, this gene was used for 
further analysis to confirm if there was not a modulation. 
To analyse if miR-196a1 promoted the cleavage of target genes mRNAs, Real-
Time PCR was performed in order to see if there was a significant fold change in 
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mRNA expression levels. Analysing the obtained results, miR-196a does not seem to 
modulate the expression of these mRNAs.  
The results for p27 are not in agreement with Sun, et al., 2012, which found a 
down-regulation of the mRNA expression of p27 in cells over-expressing hsa-miR-196a 
in a gastric cancer cell line. This may be explained with former observations that 
miRNAs may have a tissue-specific fuction. 
Western blot analysis showed a modulation of FoxO1 and p27 proteins levels 
but not of FoxO3. On the one hand, this can lead to the possibility that FoxO3 is not a 
target of miR-196a1. On the other hand, this confirms FoxO1 and p27 as targets of miR-
196a1. The results obtained indicate that in this cellular system FoxO1 and p27 are 
regulated by miR-196a1 at the protein synthesis level. 
Biological assays showed an increased proliferation in cells expressing the miR-
196a1 vector and an inhibition of this process in cells expressing the anti-miR-196a1 
vector when compared to their respective direct and indirect controls. These results are 
similar to those obtained by Luthra, et al (2008) for endometrial, esophageal and breast 
cancer cell lines. Other reports in other cellular systems have also correlate FoxO1 and 
p27 to this phenomenon, stating that a decrease in FoxO1 levels down-regulates the 
transcription of p27 thus promoting proliferation (Adachi, et al., 2007; Saramaki, et al., 
2009). Wu, et al (2012) have obtained the same results for a cancer cell line of 
colorectal carcinoma (HCT116) using hsa-miR-223.  Nevertheless, miR-196a1 has not 
induced proliferation in another cellular system using the cell line SW480 (colorectal 
carcinoma) reinforcing the statement that miRNAs have cell line specific effects 
(Schimanski, et al., 2009).  
As in this work the modulation of FoxO1 and p27 has been confirmed, this may 
be one of the ways in which miR-196a induces proliferation. 
miR-196a1 has proven to modulate cell migration in the cellular system created. 
This have also been observed in the work developed by Schimanski et al (2009). FoxO1 
has been associated with the down-regulation of Runx2, a transcription factor of genes 
associated with improved migration, and subsequently has also been associated with 
reduced migration (Potente, et al., 2005; Zhang, et al., 2011). The role of p27 in 
migration is not clear and has been proved to be very complex. Several reports point to 
modulation of this process by p27, but the results are often cell type-specific, once it can 
induce or inhibit migration depending on the molecules with which it associates 
(Besson, et al., 2004).  
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Therefore, the mechanism by which miR-196a1 induces cellular migration can 
be explained, in part, due to the down-regulation of the studied targets, especially 
FoxO1, once the influence of p27 had to be explored by other techniques. 
Cells over-expressing hsa-miR-196a1 induced larger tumours in vivo than their 
control and cells expressing the anti-miR-196a1 vector were not able to induce tumour 
formation in vivo, indicating the oncogenic potential of this miRNA. 
The vectors of hsa-miR-196a1 and anti-miR-196a1 were inserted in different 
cell lines in order to correlate the effects of over-expression or knockdown of miR-
196a1 with the PI3K/AKT pathway.  
Finally, this cellular system successfully allowed the correlation between miR-
196a1 and the PI3K/AKT pathway, once over-expression of this miRNA in a cell line 
interfered for AKT1 lead to a partial restoring of the phenotype of cells expressing 
AKT1 normally and that have a major activation of the PI3K/AKT pathway, in 
functional assays.  
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VI. Conclusions 
 
This is not a conclusive study and it opens the door to further approaches, once 
miR-196a1 may also be co-involved in other processes that lead to tumour progression 
that have not yet been studied. Additional studies can be made to access the whole miR-
196a role in NSCLC. There are some data in bibliography confirming this miRNA to be 
involved in other cellular processes (with different cellular systems) such as colony 
formation, influence in apoptosis, reduced adhesion and chemoresistance. In order to 
fully characterize the influence of this miRNA and its correlation with PI3K/AKT 
pathway in NSCLC some other studies have to be performed such as anchorage-
dependent and independent colony formation, invasion assays, adhesion assays, cell-
cycle studies and chemotherapy sensibilization assays. 
With this work, there has been proven the influence of hsa-miR-196a1 in the 
PI3K/AKT pathway, through the modulation of FoxO1 and p27 and partially recovering 
of the phenotype of active AKT in cells interfered for AKT1. The influence observed in 
proliferation and migration also confirms the oncogenic action of hsa-miR-196a1 in 
NSCLC, once it regulates processes that are associated with the first steps in tumour 
progression and it was able to modulate tumour formation in vivo. 
This can be important in further therapy strategies and diagnosis approaches and 
reconfirms the major role of PI3K/AKT pathway in NSCLC, highlighting this pathway 
has an important therapy target. 
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